Original Article
Bivalirudin during Primary PCI in Acute Myocardial Infarction
N Engl J Med 2008; 358:2218-2230May 22, 2008
- Abstract
Background
Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non−ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI). The safety and efficacy of bivalirudin in high-risk patients are unknown.
Methods
We randomly assigned 3602 patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI to treatment with heparin plus a glycoprotein IIb/IIIa inhibitor or to treatment with bivalirudin alone. The two primary end points of the study were major bleeding and combined adverse clinical events, defined as the combination of major bleeding or major adverse cardiovascular events, including death, reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter referred to as net adverse clinical events) within 30 days.
Results
Anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in a reduced 30-day rate of net adverse clinical events (9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI] 0.63 to 0.92; P=0.005), owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 0.46 to 0.77; P<0.001). There was an increased risk of acute stent thrombosis within 24 hours in the bivalirudin group, but no significant increase was present by 30 days. Treatment with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P=0.03) and death from all causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P=0.047).
Conclusions
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966.)
Media in This Article
Figure 1
Randomization, Management Strategy, and Follow-up at 30 Days.Figure 2
Time-to-Event Curves through 30 Days.Article Activity
- Article
Primary percutaneous coronary intervention (PCI) in patients with evolving ST-segment elevation myocardial infarction decreases infarct size and the rates of recurrent ischemia, reinfarction, and stroke and improves survival, as compared with pharmacologic reperfusion therapy.1,2 Nonetheless, the prognosis after primary PCI has remained essentially unchanged over the past decade, with neither stents nor other novel devices or drugs improving survival beyond that achievable with balloon angioplasty alone.3-8 Treatment with glycoprotein IIb/IIIa inhibitors may decrease the short- and long-term risk of death,9,10 and these agents are used in more than 90% of patients who undergo primary PCI in the United States and in the majority of such patients in Europe.11,12 Nonetheless, glycoprotein IIb/IIIa inhibitors increase the risk of hemorrhagic complications and thrombocytopenia,3,10,13-15 which have been strongly associated with early and late mortality.15-19
The direct thrombin inhibitor bivalirudin (Angiomax, the Medicines Company), when used instead of heparin plus glycoprotein IIb/IIIa inhibitors, has been shown in large-scale, randomized trials to reduce major and minor bleeding and thrombocytopenia while resulting in similar rates of ischemia after PCI in patients with stable angina, those with unstable angina, and those with non−ST-segment elevation myocardial infarction.20-23 Whether bivalirudin is safe and effective for patients with ST-segment elevation myocardial infarction who are undergoing primary PCI has not, to our knowledge, been studied. We therefore performed a large-scale study to evaluate the clinical value of bivalirudin in patients with ST-segment elevation myocardial infarction.
Methods
Trial
The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) study was a prospective, open-label, randomized, multicenter trial that compared bivalirudin alone with heparin plus a glycoprotein IIb/IIIa inhibitor in patients with ST-segment elevation myocardial infarction who were undergoing primary PCI. The trial was designed by the principal investigator (Dr. Stone), executive committee, and pharmacology committee and was sponsored and managed by the Cardiovascular Research Foundation, a nonprofit foundation affiliated with Columbia University (receiving funding from many commercial entities that make products for use in cardiovascular medicine, in addition to various other sources), with grant support from Boston Scientific and the Medicines Company. Other than supplying financial support and the drugs and devices, the funding companies were not involved with study processes, including site selection and management, data collection, and analysis. The principal investigator had unrestricted access to the data after the database was locked, controlled the decision to publish, prepared the manuscript, and vouches for the integrity and completeness of the trial report. No agreements exist regarding confidentiality of the data among the funding companies, the sponsor, and the investigators.
Patient Population
Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms and who had ST-segment elevation of 1 mm or more in two or more contiguous leads, new left bundle-branch block, or true posterior myocardial infarction were considered for enrollment. The principal exclusion criteria were contraindications to the study medications; prior administration of thrombolytic agents, bivalirudin, glycoprotein IIb/IIIa inhibitors, low-molecular-weight heparin, or fondaparinux for the present admission (although prior unfractionated heparin was allowed); current use of warfarin; history of bleeding diathesis, coagulopathy, heparin-induced thrombocytopenia, intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke; stroke or transient ischemic attack within the previous 6 months or any permanent neurologic deficit; refusal to receive blood transfusions; gastrointestinal or genitourinary bleeding within the previous 2 months; major surgery within the previous 6 weeks; a known platelet count of less than 100,000 cells per cubic millimeter or a hemoglobin level of less than 10 g per deciliter, a planned elective surgical procedure that would necessitate an interruption in treatment with thienopyridines during the first 6 months after enrollment; coronary stent implantation within the previous 30 days; and noncardiac coexisting conditions that could limit life expectancy to less than 1 year or that might interfere with compliance with the protocol. The study was approved by the institutional review board or ethics committee at each participating center, and all patients gave written informed consent.
Study Protocol and Randomization
Patients were randomly assigned, in an open-label fashion and in a 1:1 ratio, to treatment with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (the control group) or to treatment with bivalirudin alone (Figure 1Figure 1
Randomization, Management Strategy, and Follow-up at 30 Days.). Heparin was administered as an intravenous bolus of 60 IU per kilogram of body weight, with subsequent boluses targeted to an activated clotting time of 200 to 250 seconds. Bivalirudin was administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour. If heparin was administered in a patient in the bivalirudin group, bivalirudin was started 30 minutes later but in all cases before PCI. Both antithrombin agents were discontinued, as specified by the protocol, at the completion of angiography or PCI but could be continued at low doses if they were clinically indicated. A glycoprotein IIb/IIIa inhibitor was administered before PCI in all the patients in the control group but was to be administered in the bivalirudin group only in patients with no reflow or with giant thrombus after PCI. Either abciximab (a bolus of 0.25 mg per kilogram followed by an infusion of 0.125 μg per kilogram per minute; maximum dose, 10 μg per minute) or double-bolus eptifibatide (a bolus of 180 μg per kilogram followed by an infusion of 2.0 μg per kilogram per minute, with a second bolus given 10 minutes after the first; no maximum dose prespecified), adjusted for renal impairment according to the label, was permitted at the discretion of the investigator and was continued for 12 hours (abciximab) or 12 to 18 hours (eptifibatide).Aspirin (324 mg given orally or 500 mg administered intravenously) was given in the emergency room, after which 300 to 325 mg was given orally every day during the hospitalization, and 75 to 81 mg every day thereafter indefinitely. A loading dose of clopidogrel (either 300 mg or 600 mg, at the discretion of the investigator), or ticlopidine (500 mg), in the case of allergy to clopidogrel, was administered before catheterization, followed by 75 mg orally every day for at least 6 months (1 year or longer recommended).
Telephone randomization was performed with the use of a computerized, interactive voice-response system and a dynamic (minimization) allocation scheme that balanced the assignments for the administration of heparin before randomization; the administration of 300 mg or 600 mg of clopidogrel or 500 mg of ticlopidine before catheterization; planned administration of abciximab or eptifibatide for patients assigned to the control group; and the location of the study site (in the United States or outside the United States).
Emergency coronary angiography with left ventriculography was performed after randomization, followed by triage, at the discretion of the physician, to PCI, coronary-artery bypass grafting (CABG), or medical management, as described previously.3 After patency was restored in the infarct-related vessel, eligible patients were randomly assigned again, in a 3:1 ratio, to either paclitaxel-eluting stents (TAXUS Express,2 Boston Scientific) or uncoated, bare-metal stents that were identical in appearance (Express,2 Boston Scientific). The protocol specified that enrollment would continue until 3000 patients had been randomly assigned to a treatment group in this second part of the study. Clinical follow-up was performed at 30 days (±7 days), 6 months (±14 days), and 1 year (±14 days) and then yearly for a total of 5 years. Prespecified analyses of the primary end points were planned at 30 days for the first randomization (the pharmacologic component of the study) and at 1 year for the second randomization (the stent component). The results of the second randomization currently remain blinded, and the 30-day results reported here are based on pooled data for the stent groups. There were no significant interactions between stent type and the primary end points at 30 days in the pharmacologic component, according to an unblinded, independent statistical monitoring group.
Statistical Analysis
Two primary 30-day end points were prespecified: major bleeding (not related to coronary-artery bypass grafting) and combined adverse clinical events, defined as the combination of major bleeding or a composite of major adverse cardiovascular events, including death, reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter referred to as net adverse clinical events). Major bleeding was defined as intracranial or intraocular hemorrhage; bleeding at the access site, with a hematoma that was 5 cm or larger or that required intervention; a decrease in the hemoglobin level of 4 g per deciliter or more without an overt bleeding source or 3 g per deciliter or more with an overt bleeding source; reoperation for bleeding; or blood transfusion. Bleeding was also assessed and adjudicated on the basis of the Thrombolysis in Myocardial Infarction (TIMI) and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) scales. Major adverse cardiovascular events have been defined previously.24 Death from cardiac causes was defined as death due to acute myocardial infarction, cardiac perforation or pericardial tamponade, arrhythmia or conduction abnormality, stroke, procedural complications, or any death for which a cardiac cause could not be ruled out. Death from noncardiac causes included bleeding-related death. Stent thrombosis was defined as the definite or probable occurrence of a stent-related thrombotic event according to the Academic Research Consortium classification.25 An independent clinical events committee that was unaware of the treatment assignments adjudicated all end-point events by reviewing the medical records.
The primary analyses were performed for all patients who underwent randomization, according to the intention-to-treat principle; secondary analyses were performed for the patients who underwent primary PCI. Sequential noninferiority and superiority analysis with hierarchical end-point testing for both primary end points was prespecified, with type I error controlled by the Benjamini–Hochberg procedure.26 Noninferiority tests were based on the upper boundary of the two-sided 95% confidence interval, with the use of binomial proportions. The noninferiority margins for major bleeding and net adverse clinical events were prespecified at 1% and 3.2%, respectively. A two-sided alpha level of 0.05 was used for superiority testing. Assuming true 30-day event rates for major bleeding and net adverse clinical events of 9% and 12%, respectively, in the control group and 6% and 9%, respectively, in the bivalirudin group, with 1700 patients in each group, the trial had 99% power to show the superiority of bivalirudin for reducing the rate of major bleeding and 80% power to show its superiority for reducing the rate of net adverse clinical events.
Categorical outcomes were compared by means of the chi-square test or Fisher's exact test. Continuous variables were compared by means of the Wilcoxon rank-sum test. In addition to the primary analysis, which was based on binomial proportions, time-to-event outcomes, determined with Kaplan−Meier methods, were compared by means of the log-rank test.
Results
Patients and Procedures
Between March 25, 2005, and May 7, 2007, a total of 3602 patients, at 123 centers in 11 countries, who had ST-segment elevation myocardial infarction and were undergoing primary PCI were randomly assigned to treatment with heparin plus a glycoprotein IIb/IIIa inhibitor (1802 patients) or with bivalirudin alone (1800 patients) (Figure 1). After emergency angiography, the primary management strategy was primary PCI in 92.7% of the patients, deferred PCI in 0.2%, primary CABG in 1.7%, and medical management in 5.3%.
The baseline features of the groups were well matched (Table 1Table 1
Baseline Characteristics of the Study Population.). The median age was 60.2 years, and 76.6% of the patients were men. The infarct-related vessel was the left anterior descending artery in 40.7% of the patients who were undergoing primary PCI, and stents were implanted in 95.5% of those patients. Compliance with protocol-specified study medications was high (Table 2Table 2
Procedures and Study Medications.). Unfractionated heparin (typically a bolus without infusion) was administered before cardiac catheterization in approximately two thirds of the patients who were assigned to treatment with bivalirudin. A 600-mg loading dose of clopidogrel was used almost twice as frequently as a 300-mg dose. Glycoprotein IIb/IIIa inhibitors were administered in 129 patients (7.2%) who were assigned to bivalirudin treatment — in 47 because of a sustained absence of reflow after PCI, in 32 because of giant thrombus after PCI, and in the rest for various other clinical indications.Clinical Outcomes
At 30 days, patients who were assigned to receive bivalirudin alone, as compared with those who were assigned to receive heparin plus a glycoprotein IIb/IIIa inhibitor, had a significantly reduced rate of net adverse clinical events (9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI], 0.63 to 0.92; P=0.005), owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 0.46 to 0.77; P<0.001), with similar rates of major adverse cardiovascular events (5.4% and 5.5%, respectively; relative risk in the bivalirudin group, 0.99; 95% CI, 0.76 to 1.30; P=0.95) (Table 3Table 3
Clinical Outcomes at 30 Days. and Figure 2Figure 2Time-to-Event Curves through 30 Days.). In a post hoc analysis, with the exclusion of large hematomas from the protocol definition, the rate of major bleeding was reduced from 7.8% with heparin plus glycoprotein IIb/IIIa inhibitors to 4.7% with bivalirudin (P<0.001). Bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, also reduced hemorrhagic complications as defined by the TIMI and GUSTO scales, thrombocytopenia, and the need for blood transfusions (Table 3). Among patients in the control group, the peak activated clotting time did not differ significantly between those with major bleeding and those without major bleeding (median, 273 seconds and 263 seconds, respectively; P=0.12).Treatment with bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P=0.03) and death from all causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P=0.047); rates of reinfarction, target-vessel revascularization, and stroke were not significantly different (Table 3 and Figure 2). There were no significant differences in the peak creatine kinase level or creatine kinase MB fraction between the bivalirudin group and the group that received heparin plus glycoprotein IIb/IIIa inhibitors (median peak creatine kinase level, 1433.0 U per liter and 1428.5 U per liter, respectively; P=0.79; median peak creatine kinase MB fraction, 162.8 U per liter and 160.1 U per liter, respectively; P=0.98). There were no significant interactions between the treatment assignment and either preprocedural unfractionated-heparin use or clopidogrel loading dose with respect to major adverse cardiovascular events or major bleeding (Table 4Table 4
Adverse Events According to Medication Administration before PCI.).Among 3124 patients in whom stents were successfully implanted, the overall rate of stent thrombosis at 30 days did not differ significantly between the group that received bivalirudin and the group that received heparin plus a glycoprotein IIb/IIIa inhibitor (2.5% and 1.9%, respectively; P=0.30). However, in a prespecified analysis, within the first 24 hours, stent thrombosis occurred in 17 more patients in the bivalirudin group than in the group receiving heparin plus a glycoprotein IIb/IIIa inhibitor (1.3% vs. 0.3%, P<0.001), whereas between 24 hours and 30 days, stent thrombosis occurred in 7 fewer patients in the bivalirudin group (1.2% vs. 1.7%, P=0.28). Nonetheless, patients in whom PCI was performed and who were assigned to receive bivalirudin rather than heparin plus a glycoprotein IIb/IIIa inhibitor had lower 30-day rates of death from cardiac causes (1.8% vs. 2.8%; relative risk, 0.63; 95% CI, 0.40 to 0.99; P=0.045), major bleeding (5.1% vs. 8.5%; relative risk, 0.59; 95% CI, 0.46 to 0.77; P<0.001), and net adverse clinical events (9.2% vs. 12.2%; relative risk, 0.75; 95% CI, 0.62 to 0.92; P=0.005).
Among the 25 patients in whom stent thrombosis developed within 24 hours, 2 patients died (8.0%), including 1 in each randomized group. In the entire study cohort, of the 93 patients who died within 30 days, death was preceded by major bleeding in 26 patients, 8 of whom were in the bivalirudin group (hazard ratio for death among patients with vs. those without major bleeding, 9.12; 95% CI, 5.73 to 14.52; P<0.001) and by definite stent thrombosis in 5 patients, 1 of whom was in the bivalirudin group (hazard ratio for death among patients with vs. those without definite stent thrombosis, 5.54; 95% CI, 2.24 to 13.69; P<0.001).
Discussion
In this prospective, randomized trial involving patients with ST-segment elevation myocardial infarction who were undergoing primary PCI, treatment with the direct thrombin inhibitor bivalirudin (with glycoprotein IIb/IIIa inhibitors administered in 7.2% of the patients because of suboptimal results of the PCI), as compared with treatment with heparin plus the routine use of glycoprotein IIb/IIIa inhibitors, improved event-free survival at 30 days, owing to a significant reduction in major bleeding. The rates of major adverse cardiovascular events were similar in the two treatment groups. Bivalirudin reduced the rate of major bleeding, as classified not only by the protocol definition but also by the laboratory-based TIMI scale and the clinical GUSTO scale, and in addition reduced the rates of thrombocytopenia and blood transfusion, despite the significantly higher peak activated clotting time among patients treated with bivalirudin. Moreover, random assignment to bivalirudin alone as compared with heparin plus glycoprotein IIb/IIIa inhibitors significantly reduced the rates of death from cardiac causes and from all causes at 30 days.
The reduction in mortality with bivalirudin as compared with heparin plus glycoprotein IIb/IIIa inhibitors in the present trial may be attributable to the prevention of iatrogenic hemorrhagic complications. Previous trials have documented the independent relationship between major bleeding (with or without blood transfusions) and subsequent death.16-19 Major bleeding was a more powerful predictor of death than periprocedural myocardial infarction after PCI in the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events 2 (REPLACE-2) trial, and the reduction in bleeding with bivalirudin as compared with heparin plus glycoprotein IIb/IIIa inhibitors resulted in a trend toward reduced late mortality after PCI among the relatively low-risk patients in that study.27 In the present trial, more deaths occurred after major bleeding (26 deaths) than after reinfarction (10) or definite stent thrombosis (5). The 40% relative reduction in major bleeding in the bivalirudin group as compared with the group that received heparin plus a glycoprotein IIb/IIIa inhibitor, with similar rates of ischemic complications, may thus explain the observed improvement in survival with bivalirudin in patients with ST-segment elevation myocardial infarction, who are at higher risk than the patients in the REPLACE-2 trial. Moreover, anticoagulation with bivalirudin reduced the occurrence of severe thrombocytopenia, which has also been strongly associated with death among patients with ST-segment elevation myocardial infarction and with PCI.14,15
Among patients in whom a stent was successfully implanted, assignment to bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in 17 more episodes of stent thrombosis within the first 24 hours, representing a significant 1.0% absolute increase, which was partially offset by 7 fewer events in the patients treated with bivalirudin between 24 hours and 30 days (absolute reduction, 0.5%). The early increase in stent thrombosis with bivalirudin alone may be explained by adenosine diphosphate–induced platelet activation before maximal thienopyridine blockade of the P2Y12 receptor28 or by residual thrombin activity after the discontinuation of bivalirudin. However, although the increase in acute thrombotic events probably underlies the increased risk of major adverse cardiovascular events that was noted on the first day among patients treated with bivalirudin, the overall 30-day rates of reinfarction were not increased — 1.8% in each group — and only 2 of the 93 deaths in the study occurred after acute stent thrombosis (1 in each randomized group). The prognostic implications of acute stent thrombosis that occurs early in the hospital phase in closely monitored patients who have undergone primary PCI for ST-segment elevation myocardial infarction and that affects a previously infarcted myocardial territory may thus differ from the implications of subacute stent thrombosis or acute thrombosis that occurs after discharge from the hospital in patients who have undergone elective PCI and whose left ventricular function was well preserved. Most important, the rate of death from cardiac causes (including deaths due to stent thrombosis) among patients who were treated with heparin plus a glycoprotein IIb/IIIa inhibitor surpassed that among patients treated with bivalirudin by day 7, and by 30 days, a significant 37.9% relative reduction in death from cardiac causes (an absolute decrease of 1.1%) was seen in the group treated with bivalirudin. Further investigation is warranted to determine whether the risk of early stent thrombosis can be mitigated by treatment with more rapidly acting and potent thienopyridine agents,29,30 a longer course of bivalirudin, or both, without increasing the risk of bleeding. Pending such studies, the 1% incremental risk of stent thrombosis within the first 24 hours, with no significant difference in the rates at 30 days, must be placed in the context of the decrease in the rate of major bleeding and the subsequent 1% absolute reduction in mortality from cardiac causes that were achieved with the abbreviated use of bivalirudin (i.e., only during PCI) as compared with heparin plus glycoprotein IIb/IIIa inhibitors.
The present study has several strengths, including the enrollment of a broad cross section of patients. Nonetheless, several limitations should be noted. First, the logistic complexities of the trial necessitated an open-label design, introducing potential bias. However, compliance with the protocol procedure and the study medications was high, and the rate of provisional use of glycoprotein IIb/IIIa inhibitors in the bivalirudin group was low and similar to that in the double-blind REPLACE-2 trial.20 The relative reductions in hemorrhagic complications with bivalirudin as compared with heparin plus glycoprotein IIb/IIIa inhibitors in the present trial were also similar to those in the REPLACE-2 trial.20 Potential bias was further mitigated by the use of blinded core laboratories and a clinical-event adjudication committee that required original-source documentation for event verification. Second, a heparin bolus was administered in the emergency room to approximately two thirds of the patients, with bivalirudin most commonly started in the cardiac catheterization laboratory 30 minutes later, before PCI. Interaction testing, however, showed that administration of bivalirudin significantly reduced major bleeding independently of preprocedural administration of heparin, and preprocedural administration of heparin before bivalirudin was associated with a weak trend toward reduced major adverse cardiovascular events at 30 days. Third, the trial was underpowered for low-frequency end points, including death. However, the mechanistic underpinnings for the observed reduction in the rate of death with bivalirudin (i.e., reduced risks of bleeding, transfusion, and thrombocytopenia), in concert with the consistency of our results with those of earlier studies,20-23 provide reassurance that this finding is probably valid. Fourth, reinfarction may be difficult to detect after primary PCI, although the nearly identical peak levels of cardiac enzymes after PCI in the two treatment groups suggest that there was no difference in the rate of reinfarction. Finally, although an independent, unblinded statistical monitoring group has found no interactions between the type of stent used and the randomly assigned study drug for the primary 30-day end points, longer-term follow-up, including unblinding of the stent randomization data at 1 year, is required to evaluate thoroughly the effect of bivalirudin in patients with ST-segment elevation myocardial infarction who are undergoing primary PCI.
In conclusion, our trial shows that in patients with evolving ST-segment elevation myocardial infarction who are undergoing primary PCI, the use of bivalirudin alone, as compared with heparin plus a glycoprotein IIb/IIIa inhibitor, results in significantly reduced 30-day rates of major bleeding and increased event-free survival.
Supported by the Cardiovascular Research Foundation, with grant support from Boston Scientific and the Medicines Company.
Dr. Stone reports receiving consulting fees from Medtronic, GlaxoSmithKline, Eli Lilly, and Bristol-Myers Squibb and grant support from Boston Scientific, the Medicines Company, and Abbott Vascular. Dr. Guagliumi reports receiving consulting fees from or serving on advisory boards for Abbott Vascular and Boston Scientific and receiving grant support from Medtronic and Boston Scientific. Dr. Dudek reports receiving lecture fees from Nycomed. Dr. Gersh reports receiving consulting fees from or serving on advisory boards for AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories, and Boston Scientific and having equity interest in CV Therapeutics. Dr. Pocock reports receiving consulting fees from and serving on an advisory board for the Medicines Company. Dr. Kirtane reports receiving consulting fees from or serving on advisory boards for Abbott Vascular, Medtronic, and Boston Scientific and receiving lecture fees from the Medicines Company and Alphamedica. Dr. Mehran reports receiving lecture fees from Boston Scientific and the Medicines Company. Dr. Parise reports being employed by the Cardiovascular Research Foundation.
No other potential conflict of interest relevant to this article was reported.
The investigators, institutions, and research organizations participating in the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial are listed in the Appendix.
Source Information
From Columbia University Medical Center and the Cardiovascular Research Foundation, New York (G.W.S., G.D., A.J.K., H.P., R.M.); Charité Campus Benjamin Franklin, Berlin (B.W.); Ospedali Riuniti di Bergamo, Bergamo, Italy (G.G.); Silesian Center for Heart Disease, Lodz, Poland (J.Z.P.); LeBauer Cardiovascular Research Foundation and Moses Cone Hospital, Greensboro, NC (B.R.B.); Jagiellonian University, Krakow, Poland (D.D.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Universitätsklinikum Schleswig-Holstein, Lübeck, Germany (F.H.); Mayo Clinic, Rochester, MN (B.J.G.); London School of Hygiene and Tropical Medicine, London (S.J.P.); and New York−Presbyterian Hospital/Weill Cornell Medical Center, New York (S.C.W.).
Address reprint requests to Dr. Stone at Columbia University Medical Center, Cardiovascular Research Foundation, 111 E. 59th St., 11th Fl., New York, NY 10022, or at gs2184@columbia.edu.
Appendix
The following investigators and institutions participated in the HORIZONS-AMI Trial: Executive Committee: G.W. Stone (principal investigator and chair), Columbia University Medical Center and the Cardiovascular Research Foundation, New York; B.R. Brodie, LeBauer Cardiovascular Research Foundation and Moses Cone Hospital, Greensboro, NC; D.A. Cox, Mid Carolina Cardiology, Charlotte, NC; C.L. Grines, William Beaumont Hospital, Royal Oak, MI; B.D. Rutherford, St. Luke's Hospital, Kansas City, MO. Pharmacology Committee: D. Bhatt, Cleveland Clinic Foundation, Cleveland; G. Dangas, Columbia University Medical Center and the Cardiovascular Research Foundation, New York; F. Feit, New York University, New York; M. Ohman, Duke University Medical Center, Durham, NC. European Steering Committee: H. Bonnier, Catharina Hospital, Eindhoven, the Netherlands; A. Colombo, Colombus Hospital, Milan; E. Garcia, Hospital Universitario Gregorio Maranon, Madrid; E. Grube, Heart Center Siegburg, Siegburg, Germany; G. Guagliumi, Ospedali Riuniti di Bergamo, Bergamo, Italy; A. Kastrati, Deutsches Herzzentrum, Technische Universität, Munich, Germany; P. Serruys, Thoraxcenter, Rotterdam, the Netherlands; H. Suryapranata, Hospital De Weezenlanden, Zwolle, the Netherlands. Country Leaders: the Netherlands: H. Bonnier and H. Suryapranata; Italy: A. Colombo and G. Guagliumi; Spain: E. Garcia; Germany: E. Grube and A. Kastrati; Israel: Y. Almagor; United Kingdom: A. Banning; Argentina: J. Belardi, L. Grinfeld; Poland: D. Dudek; Austria: K. Huber; Norway: D. Nilsen; Sweden: G. Olivecrona; Denmark: L. Rasmussen. Clinical Endpoints Committee: Cardiovascular Research Foundation Data Center, New York, S.C. Wong (chair). Field Officers: M. Farkouh (chair), M. Attubato, G. Dangas, F. Feit, R. Mehran. Site Management and Data Monitoring: J. Tyson and Associates (U.S.), D-Target (Europe), Tango (South America). Data Management: E-trials, Morrisville, NC, D. Winsted (manager). Data Coordination and Analysis: Cardiovascular Research Foundation Data Center, New York, R. Mehran (director), I. Bihl (operations), H. Parise (statistics). Data Safety and Monitoring Board: B.J. Gersh (chair), Mayo Clinic, Rochester, MN; D. Faxon, Brigham and Women's Hospital, Boston; S. King, Fuqua Heart Center, Atlanta; S.J. Pocock, London School of Hygiene and Tropical Medicine, London; D.O. Williams, Rhode Island Hospital, Providence, RI. Qualitative and Quantitative Coronary Angiographic Core Laboratory Analysis: Cardiovascular Research Foundation, New York, A.J. Lansky (director), E. Cristea (operations). Qualitative and Quantitative Electrocardiographic Core Laboratory Analysis: Cardiovascular Research Foundation, New York, J. Reiffel (director). Intravascular Ultrasound Core Laboratory Analysis: Cardiovascular Research Foundation, New York, G. Mintz (director). Biomarker Substudy Core Laboratory: BioSite, San Diego, CA.
For a full list of participating countries (with total enrollment), hospitals, and principal investigators, see the Supplementary Appendix (available with the full text of this article at www.nejm.org).
- References
References
1
Keeley EC ,Boura JA ,Grines CL . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20
CrossRef | Web of Science | Medline2
Schomig A ,Neumann FJ ,Kastrati A , et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089
Full Text | Web of Science | Medline3
Stone GW ,Grines CL ,Cox DA , et al. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966
Full Text | Web of Science | Medline4
De Luca G ,Suryapranata H ,Ottervanger JP , et al. Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Int J Cardiol 2007;119:306-309
CrossRef | Medline5
De Luca G ,Suryapranata H ,Stone GW ,Antoniucci D ,Neumann FJ ,Chiarello M . Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J 2007;153:343-353
CrossRef | Web of Science | Medline6
Ross AM ,Gibbons RJ ,Stone GW ,Kloner RA ,Alexander RW . A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780
CrossRef | Web of Science | Medline7
Armstrong PW ,Granger CB ,Adams PX , et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51
CrossRef | Web of Science | Medline8
Alexander JH ,Reynolds HR ,Stebbins AL , et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007;297:1657-1666
CrossRef | Web of Science | Medline9
De Luca G ,Suryapranata H ,Stone GW , et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765
CrossRef | Web of Science | Medline10
Kandzari DE ,Hasselblad V ,Tcheng JE , et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J 2004;147:457-462
CrossRef | Web of Science | Medline11
Dauerman HL ,Frederick PD ,Miller D ,French WJ . Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis 2007;18:141-148
CrossRef | Web of Science | Medline12
Fox KA ,Steg PG ,Eagle KA , et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-1900
CrossRef | Web of Science | Medline13
Montalescot G ,Barragan P ,Wittenberg O , et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903
Full Text | Web of Science | Medline14
Kereiakes DJ ,Berkowitz SD ,Lincoff AM , et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74-80
CrossRef | Web of Science | Medline15
Nikolsky E ,Grines CL ,Cox DA , et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol 2007;99:1055-1061
CrossRef | Web of Science | Medline16
Eikelboom JW ,Mehta SR ,Anand SS ,Xie C ,Fox KA ,Yusuf S . Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-782
CrossRef | Web of Science | Medline17
Kinnaird TD ,Stabile E ,Mintz GS , et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-935
CrossRef | Web of Science | Medline18
Rao SV ,Jollis JG ,Harrington RA , et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562
CrossRef | Web of Science | Medline19
Manoukian SV ,Feit F ,Mehran R , et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 2007;49:1362-1368
CrossRef | Web of Science | Medline20
Lincoff AM ,Bittl JA ,Harrington RA , et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863[Erratum, JAMA 2003;289:1638.]
CrossRef | Web of Science | Medline21
Lincoff AM ,Kleiman NS ,Kereiakes DJ , et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703[Erratum, JAMA 2006;296:46.]
CrossRef | Web of Science | Medline22
Stone GW ,McLaurin BT ,Cox DA , et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216
Full Text | Web of Science | Medline23
Stone GW ,Ware JH ,Bertrand ME , et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-2506
CrossRef | Web of Science | Medline24
Stone GW ,Bertrand M ,Colombo A , et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004;148:764-775
CrossRef | Web of Science | Medline25
Cutlip DE ,Windecker S ,Mehran R , et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351
CrossRef | Web of Science | Medline26
Benjamini Y ,Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc [B] 1995;57:289-30027
Feit F ,Voeltz MD ,Attubato MJ , et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol 2007;100:1364-1369
CrossRef | Web of Science | Medline28
Gurbel PA ,Bliden KP ,Zaman KA ,Yoho JA ,Hayes KM ,Tantry US . Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159
CrossRef | Web of Science | Medline29
Wiviott SD ,Braunwald E ,McCabe CH , et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
Full Text | Web of Science | Medline30
Greenbaum AB ,Ohman EM ,Gibson CM , et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154:702-709
CrossRef | Web of Science | Medline
- Citing Articles (325)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
Fadi Matar, Jad Mroue. (2012) The Management of Thrombotic Lesions in the Cardiac Catheterization Laboratory. Journal of Cardiovascular Translational Research 5:1, 52-61
CrossRef3
Charles Knight, Adam D. Timmis. (2012) Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia (English Edition) 31:2, 179-188
CrossRef4
Basar Candemir, Mustafa Kilickap, Ozgur Ulas Ozcan, Cansin Tulunay Kaya, Menekse Gerede, Aydan Ongun Ozdemir, Cagdas Ozdol, Deniz Kumbasar, Cetin Erol. (2012) Intracoronary versus intravenous high-dose bolus plus maintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction. Journal of Thrombosis and Thrombolysis
CrossRef5
B. E. Claessen, G. D. Dangas, G. Weisz, B. Witzenbichler, G. Guagliumi, M. Mockel, S. J. Brener, K. Xu, J. P. S. Henriques, R. Mehran, G. W. Stone. (2012) Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. European Heart Journal
CrossRef6
Fadi Saab, Costin Ionescu, Marc J. Schweiger. (2012) Bleeding risk and safety profile related to the use of eptifibatide : a current review. Expert Opinion on Drug Safety1-10
CrossRef7
Marco Valgimigli, Francesco Saia, Paolo Guastaroba, Alberto Menozzi, Paolo Magnavacchi, Andrea Santarelli, Francesco Passerini, Pietro Sangiorgio, Antonio Manari, Fabio Tarantino, Massimo Margheri, Alberto Benassi, Massimo Giuseppe Sangiorgi, Stefano Tondi, Antonio Marzocchi. (2012) Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction. JACC: Cardiovascular Interventions 5:1, 23-35
CrossRef8
Robert A. Leonardi, Jacob C. Townsend, D. Dirk Bonnema, Chetan A. Patel, Michael T. Gibbons, Thomas M. Todoran, Christopher D. Nielsen, Eric R. Powers, Daniel H. Steinberg. (2012) Comparison of Percutaneous Coronary Intervention Safety Before and During the Establishment of a Transradial Program at a Teaching Hospital. The American Journal of Cardiology
CrossRef9
Mohamed Abdel-Wahab, Gert Richardt. (2012) Safety of bivalirudin in patients with coronary artery disease. Expert Opinion on Drug Safety 11:1, 141-150
CrossRef10
Marco Tubaro, Nicolas Danchin, Patrick Goldstein, Gerasimos Filippatos, Yonathan Hasin, Magda Heras, Petr Jansky, Tone M. Norekval, Eva Swahn, Kristian Thygesen, Christiaan Vrints, Doron Zahger, Hans R. Arntz, Abdelouahab Bellou, Jean E. De La Coussaye, Leonardo De Luca, Kurt Huber, Yves Lambert, Maddalena Lettino, Bertil Lindahl, Scott Mclean, Lutz Nibbe, William F. Peacock, Susanna Price, Tom Quinn, Christian Spaulding, Gabriel Tatu-Chitoiu, Frans Van De Werf. (2012) Tratamiento prehospitalario de los pacientes con IAMCEST. Una declaración científica del Working Group Acute Cardiac Care de la European Society of Cardiology. Revista Española de Cardiología 65:1, 60-70
CrossRef11
Michael M. Hirschl, Harald Mayr, Friedrich Erhart, Walter Brunner, Friedrich Steger, Martin Gattermeier, Franz Pfeffel. (2012) Prehospital treatment of patients with acute myocardial infarction with bivalirudin. The American Journal of Emergency Medicine 30:1, 12-17
CrossRef12
S. D. Kristensen, M. Würtz, E. L. Grove, R. De Caterina, K. Huber, D. J. Moliterno, F.-J. Neumann. (2012) Contemporary use of glycoprotein IIb/IIIa inhibitors. Thrombosis and Haemostasis 107:2,
CrossRef13
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Jennifer Yu, Helen Parise, Ke Xu, Stuart J. Pocock, Gregg W. Stone. (2011) Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). The American Journal of Cardiology
CrossRef14
Yung-Lung Chen, Chia-Lo Chang, Huang-Chung Chen, Cheuk-Kwan Sun, Kuo-Ho Yeh, Tzu-Hsien Tsai, Chien-Jen Chen, Shyh-Ming Chen, Cheng-Hsu Yang, Chi-Ling Hang, Chiung-Jen Wu, Hon-Kan Yip. (2011) Major Adverse Upper Gastrointestinal Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention and Dual Antiplatelet Therapy. The American Journal of Cardiology 108:12, 1704-1709
CrossRef15
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef16
, B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer. (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. Der Kardiologe 5:6, 411-435
CrossRef17
Chee Tang Chin, William S. Weintraub, David Dai, Rajendra H. Mehta, John S. Rumsfeld, H. Vernon Anderson, John C. Messenger, Michael A. Kutcher, Eric D. Peterson, Ralph G. Brindis, Sunil V. Rao. (2011) Trends and predictors of length of stay after primary percutaneous coronary intervention: A report from the CathPCI Registry. American Heart Journal 162:6, 1052-1061
CrossRef18
Rajendra H. Mehta, Jennifer Yu, Jonathan P. Piccini, James E. Tcheng, Michael E. Farkouh, James Reiffel, Martin Fahy, Roxana Mehran, Gregg W. Stone. (2011) Prognostic Significance of Postprocedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). The American Journal of Cardiology
CrossRef19
Marieke L. Fokkema, Wouter G. Wieringa, Iwan C. van der Horst, Eric Boersma, Felix Zijlstra, Bart J. de Smet. (2011) Quantitative Analysis of the Impact of Total Ischemic Time on Myocardial Perfusion and Clinical Outcome in Patients With ST-Elevation Myocardial Infarction. The American Journal of Cardiology 108:11, 1536-1541
CrossRef20
Philippe Généreux, Roxana Mehran, Tullio Palmerini, Adriano Caixeta, Ajay J. Kirtane, Alexandra J. Lansky, Bruce R. Brodie, Bernhard Witzenbichler, Martin Mockel, Giulio Guagliumi, Jan Z. Peruga, Dariusz Dudek, Martin P Fahy, George Dangas, Gregg W. Stone. (2011) Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 7:8, 905-916
CrossRef21
Thomas Cuisset, Mathieu Pankert, Jacques Quilici. (2011) Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients. Journal of Cardiovascular Medicine 12:12, 860-867
CrossRef22
Andreas Baumbach, Thomas W. Johnson, Valentino Oriolo, Sujatha Kesavan, Alan Davis, David Smith, John Edmond, Barnaby C. Reeves, Julian W. Strange. (2011) Prasugrel and bivalirudin for primary angioplasty: Early results on stent thrombosis and bleeding. International Journal of Cardiology 153:2, 222-224
CrossRef23
Martin Möckel, Jörn Vollert, Alexandra J. Lansky, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Bruce R. Brodie, Ran Kornowski, Dariusz Dudek, Michael E. Farkouh, Helen Parise, Roxana Mehran, Gregg W. Stone. (2011) Comparison of Direct Stenting With Conventional Stent Implantation in Acute Myocardial Infarction. The American Journal of Cardiology 108:12, 1697-1703
CrossRef24
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef25
Anupama Shivaraju, Vikas Patel, Gregg C. Fonarow, Hui Xie, Adhir R. Shroff, Mladen I. Vidovich. (2011) Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: Analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. American Heart Journal 162:6, 1062-1068.e5
CrossRef26
Stavros Apostolakis, Gregory YH Lip, Deirdre A Lane, Eduard Shantsila. (2011) The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics 29:6, e12-e22
CrossRef27
É. Bonnefoy, G. Kirkorian. (2011) La mortalité des syndromes coronariens aigus. Annales de Cardiologie et d'Angéiologie 60:6, 311-316
CrossRef28
Gregg W Stone, Roxana Mehran. (2011) Bivalirudin for patients with ST-elevation myocardial infarction – Authors' reply. The Lancet 378:9807, 1915-1916
CrossRef29
Charles Knight, Adam D. Timmis. (2011) Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia
CrossRef30
Kastrati, Adnan, Neumann, Franz-Josef, Schulz, Stefanie, Massberg, Steffen, Byrne, Robert A., Ferenc, Miroslaw, Laugwitz, Karl-Ludwig, Pache, Jürgen, Ott, Ilka, Hausleiter, Jörg, Seyfarth, Melchior, Gick, Michael, Antoniucci, David, Schömig, Albert, Berger, Peter B., Mehilli, Julinda, . (2011) Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction. New England Journal of Medicine 365:21, 1980-1989
Full Text31
Ronald P. Caputo, Jennifer A. Tremmel, Sunil Rao, Ian C. Gilchrist, Christopher Pyne, Samir Pancholy, Douglas Frasier, Rajiv Gulati, Kimberly Skelding, Olivier Bertrand, Tejas Patel. (2011) Transradial arterial access for coronary and peripheral procedures: Executive summary by the transradial committee of the SCAI. Catheterization and Cardiovascular Interventions 78:6, 823-839
CrossRef32
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef33
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology 27:6, S402-S412
CrossRef34
João Brito, Manuel Almeida, Rui Campante Teles, Pedro Sousa, João Abecasis, Rita Calé, Pedro Gonçalves, Luís Raposo, Miguel Mendes. (2011) Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. Revista Portuguesa de Cardiologia (English Edition) 30:11, 813-819
CrossRef35
Michael S. Lee, Seung-Jung Park, David E. Kandzari, Ajay J. Kirtane, William F. Fearon, Emmanouil S. Brilakis, Paul Vermeersch, Young-Hak Kim, Ron Waksman, Julinda Mehilli, Laura Mauri, Gregg W. Stone. (2011) Reply. JACC: Cardiovascular Interventions 4:11, 1250-1251
CrossRef36
Charles V. Pollack, Gerard X. Brogan, Marc Cohen, Deborah Diercks, Cindy Grines, Timothy D. Henry, Neal S. Kleiman, Robert P. Giugliano. (2011) ED to catheterization laboratory: a roundtable integrating trials with practice. The American Journal of Emergency Medicine 29:9, 1203-1216
CrossRef37
Piotr P. Buszman, Wojciech Wojakowski, Krzysztof Milewski, Marcin Dębiński, Jacek Pająk, Michael S. Aboodi, Wanda Jackiewicz, Magdalena Kawka, Andrzej Bochenek, Jayne Prats, Juan F. Granada, Greg L. Kałuża, Pawel E. Buszman. (2011) Controlled Reperfusion with Intravenous Bivalirudin and Intracoronary Abciximab Combination Therapy in the Porcine Myocardial Infarction Model. Thrombosis Research
CrossRef38
Joshua M. Stolker, David J. Cohen, Jason B. Lindsey, Kevin F. Kennedy, Neal S. Kleiman, Steven P. Marso. (2011) Mode of death after contemporary percutaneous coronary intervention: A report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. American Heart Journal 162:5, 914-921
CrossRef39
Sukhdeep S. Basra, Peter Tsai, Nasser M. Lakkis. (2011) Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:22, 2263-2269
CrossRef40
D. Divchev, C. Nienaber, H. Ince. (2011) Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen. Der Internist 52:11, 1292-1300
CrossRef41
João Brito, Manuel Almeida, Rui Campante Teles, Pedro Sousa, João Abecasis, Rita Calé, Pedro Gonçalves, Luís Raposo, Miguel Mendes. (2011) Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. Revista Portuguesa de Cardiologia 30:11, 813-819
CrossRef42
Michael S. Lee, Hsini Liao, Tae Yang, Jashdeep Dhoot, Jonathan Tobis, Gregg Fonarow, Ehtisham Mahmud. (2011) Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials. International Journal of Cardiology 152:3, 369-374
CrossRef43
Kenji Goto, Eugenia Nikolsky, Alexandra J. Lansky, George Dangas, Bernhard Witzenbichler, Helen Parise, Giulio Guagliumi, Ran Kornowski, Bimmer E. Claessen, Martin Fahy, Roxana Mehran, Gregg W. Stone. (2011) Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal of Cardiology 108:10, 1387-1394
CrossRef44
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef45
So-Yeon Choi, Akiko Maehara, Ecaterina Cristea, Bernhard Witzenbichler, Giulio Guagliumi, Bruce Brodie, Mirle A. Kellett, Ovidiu Dressler, Alexandra J. Lansky, Helen Parise, Roxana Mehran, Gary S. Mintz, Gregg W. Stone. (2011) Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). The American Journal of Cardiology
CrossRef46
N. Assez, E. Wiel, C. Lemanski-Brulin, C. Adriansen, P. Goldstein. (2011) Syndromes coronariens aigus : prise en charge thérapeutique en urgence. Annales françaises de médecine d'urgence
CrossRef47
Steffen Desch, Annelie Siegemund, Ute Scholz, Natalie Adam, Ingo Eitel, Suzanne Waha, Georg Fürnau, Philipp Lurz, Sabrina Wetzel, Gerhard Schuler, Holger Thiele. (2011) Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clinical Research in Cardiology
CrossRef48
H. D. White. (2011) Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. European Heart Journal
CrossRef49
Rafael Romaguera, Gabriel Sardi, Ana Laynez-Carnicero, Itsik Ben-Dor, Gabriel Maluenda, Kohei Wakabayashi, Camille Hauville, Rebecca Torguson, Zhenyi Xue, Kenneth M. Kent, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2011) Outcomes of Coronary Arterial Perforations During Percutaneous Coronary Intervention With Bivalirudin Anticoagulation. The American Journal of Cardiology 108:7, 932-935
CrossRef50
Daria Mochly-Rosen, Kevin V. Grimes. (2011) Myocardial salvage in acute myocardial infarction - Challenges in clinical translation. Journal of Molecular and Cellular Cardiology 51:4, 451-453
CrossRef51
Sorin J. Brener, Roxana Mehran, Bruce R. Brodie, Giulio Guagliumi, Bernhard Witzenbichler, Ecaterina Cristea, Ke Xu, Alexandra J. Lansky, Gregg W. Stone. (2011) Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). The American Journal of Cardiology 108:7, 918-923
CrossRef52
Damian J. Kelly, Tony Gershlick, Bernhard Witzenbichler, Giulio Guagliumi, Martin Fahy, George Dangas, Roxana Mehran, Gregg W. Stone. (2011) Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. American Heart Journal 162:4, 663-670
CrossRef53
Giuseppe De Luca. (2011) Glycoprotein IIb-IIIa Inhibitors. Cardiovascular Therapeuticsno-no
CrossRef54
Inder M. Singh, David R. Holmes. (2011) Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. Current Problems in Cardiology 36:10, 375-401
CrossRef55
BERNARDO CORTESE. (2011) The Original Sin Committed in Years Two Thousand. Journal of Interventional Cardiology 24:5, 424-425
CrossRef56
H. Benjamin Starnes, Ankit A. Patel, George A. Stouffer. (2011) Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions. Drugs 71:15, 2009-2030
CrossRef57
David Planer, Roxana Mehran, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Bruce R. Brodie, Dariusz Dudek, Martin Möckel, Selene Leon Reyes, Gregg W. Stone. (2011) Prognostic Utility of Left Ventricular End-Diastolic Pressure in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of Cardiology 108:8, 1068-1074
CrossRef58
Piotr Musialek, Lukasz Tekieli, Piotr Pieniazek, Anetta Undas, Tomasz Miszalski-Jamka, Wojciech Zajdel, Piotr Klimeczek, Bartosz Laskowicz, R. Pawel Banys, Mieczyslaw Pasowicz, Piotr Podolec. (2011) How should I treat a very large thrombus burden in the infarct-related artery in a young patient with an unexplained lower GI tract bleeding?. EuroIntervention 7:6, 754-763
CrossRef59
Daniel P. Kessler, Eugene Kroch, Mark A. Hlatky. (2011) The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. American Heart Journal 162:3, 494-500.e2
CrossRef60
Dominique Joyal, Mark J. Eisenberg. (2011) Upstream Treatment of ST-Segment Elevation Myocardial Infarction: The Role of Glycoprotein IIb/IIIa Inhibitors. Canadian Journal of Cardiology 27:5, 534-535
CrossRef61
Ankur Sethi, Amol Bahekar, Hardik Doshi, Rohit Bhuriya, Updesh Bedi, Sarabjeet Singh, Sandeep Khosla. (2011) Tirofiban Use With Clopidogrel and Aspirin Decreases Adverse Cardiovascular Events After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials. Canadian Journal of Cardiology 27:5, 548-554
CrossRef62
Adam J. Saltzman, Gregg W. Stone, Bimmer E. Claessen, Amar Narula, Selene Leon-Reyes, Giora Weisz, Bruce Brodie, Bernhard Witzenbichler, Giulio Guagliumi, Ran Kornowski, Dariusz Dudek, D. Christopher Metzger, Alexandra J. Lansky, Eugenia Nikolsky, George D. Dangas, Roxana Mehran. (2011) Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 4:9, 1011-1019
CrossRef63
Daniel S. Menees, Eric R. Bates. (2011) Interventional cardiology: Antithrombotic drug and stent choices in primary PCI. Nature Reviews Cardiology 8:9, 483-484
CrossRef64
Ameer E. Hassan, Muhammad Zeeshan Memon, Alexandros L. Georgiadis, Gabriela Vazquez, M. Fareed K. Suri, Adnan I. Qureshi. (2011) Safety and Tolerability of High-Intensity Anticoagulation with Bivalirudin During Neuroendovascular Procedures. Neurocritical Care 15:1, 96-100
CrossRef65
Stefanie Schulz, Julinda Mehilli, Gjin Ndrepepa, Franz Dotzer, Michael Dommasch, Sebastian Kufner, Kathrin A. Birkmeier, Klaus Tiroch, Robert A. Byrne, Albert Schömig, Adnan Kastrati. (2011) Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clinical Research in Cardiology 100:8, 691-699
CrossRef66
Usman Baber, Jason Kovacic, Annapoorna S. Kini, Samin K. Sharma, George Dangas, Roxana Mehran. (2011) How Serious a Problem is Bleeding in Patients with Acute Coronary Syndromes?. Current Cardiology Reports 13:4, 312-319
CrossRef67
Ran Kornowski, Roxana Mehran, George Dangas, Eugenia Nikolsky, Abid Assali, Bimmer E. Claessen, Bernard J. Gersh, S. Chiu Wong, Bernhard Witzenbichler, Giulio Guagliumi, Dariusz Dudek, Martin Fahy, Alexandra J. Lansky, Gregg W. Stone. (2011) Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology 58:7, 704-711
CrossRef68
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao. (2011) The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation 1:8, 1155-1165
CrossRef69
P. G. Steg, K. Huber, F. Andreotti, H. Arnesen, D. Atar, L. Badimon, J.-P. Bassand, R. De Caterina, J. A. Eikelboom, D. Gulba, M. Hamon, G. Helft, K. A. A. Fox, S. D. Kristensen, S. V. Rao, F. W. A. Verheugt, P. Widimsky, U. Zeymer, J.-P. Collet. (2011) Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 32:15, 1854-1864
CrossRef70
Gilles Montalescot, Uwe Zeymer, Johanne Silvain, Bertrand Boulanger, Marc Cohen, Patrick Goldstein, Patrick Ecollan, Xavier Combes, Kurt Huber, Charles Pollack, Jean-François Bénezet, Olivier Stibbe, Emmanuelle Filippi, Emmanuel Teiger, Guillaume Cayla, Simon Elhadad, Frédéric Adnet, Tahar Chouihed, Sébastien Gallula, Agnès Greffet, Mounir Aout, Jean-Philippe Collet, Eric Vicaut. (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. The Lancet 378:9792, 693-703
CrossRef71
MICHAEL MAHMOUDI, CEDRIC DELHAYE, KOHEI WAKABAYASHI, REBECCA TORGUSON, ZHENYI XUE, WILLIAM O. SUDDATH, LOWELL F. SATLER, KENNETH M. KENT, AUGUSTO D. PICHARD, RON WAKSMAN. (2011) Integrilin in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of Interventional Cardiology 24:4, 351-356
CrossRef72
Shaun Bhatty, Richard Cooke, Ranjith Shetty, Ion S Jovin. (2011) Femoral vascular access-site complications in the cardiac catheterization laboratory: diagnosis and management. Interventional Cardiology 3:4, 503-514
CrossRef73
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef74
Peter Larsen, Saumil Shah, Sergio Waxman, Mark Freilich, Nabila Riskalla, Thomas Piemonte, Cathy Jeon, Christopher Pyne. (2011) Comparison of procedural times, success rates, and safety between left versus right radial arterial access in primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions 78:1, 38-44
CrossRef75
Ahmed A. Khattab, Gjin Ndrepepa, Stefanie Schulz, Franz-Josef Neumann, Julinda Mehilli, Heinz Joachim Büttner, Jürgen Pache, Melchior Seyfarth, Josef Dirschinger, Adnan Kastrati, Peter B. Berger, Albert Schömig, Gert Richardt. (2011) Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clinical Research in Cardiology 100:7, 579-585
CrossRef76
Bernhard Witzenbichler, Roxana Mehran, Giulio Guagliumi, Dariusz Dudek, Kurt Huber, Ran Kornowski, Thomas D. Stuckey, Martin Fahy, Helen Parise, Gregg W. Stone. (2011) Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. JACC: Cardiovascular Interventions 4:7, 760-768
CrossRef77
Aiden O'Loughlin, Alan Yeung. 2011. Percutaneous Interventions. , 340-359.
CrossRef78
Lynette R. Moser, Carrie W. Nemerovski, Kelley L. Good. (2011) Use of Prolonged Bivalirudin Infusions Following Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy 25:3, 267-276
CrossRef79
M. Tubaro, N. Danchin, P. Goldstein, G. Filippatos, Y. Hasin, M. Heras, P. Jansky, T. M. Norekval, E. Swahn, K. Thygesen, C. Vrints, D. Zahger, H. R. Arntz, A. Bellou, J. E. de La Coussaye, L. de Luca, K. Huber, Y. Lambert, M. Lettino, B. Lindahl, S. McLean, L. Nibbe, W. F. Peacock, S. Price, T. Quinn, C. Spaulding, G. Tatu-Chitoiu, F. van de Werf. (2011) Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology. Acute Cardiac Care 13:2, 56-67
CrossRef80
Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z Peruga, Bruce R Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, Bernard J Gersh, Stuart J Pocock, George Dangas, S Chiu Wong, Martin Fahy, Helen Parise, Roxana Mehran. (2011) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 377:9784, 2193-2204
CrossRef81
Avshalom Cohen, Olivier F Bertrand, David Meerkin. (2011) Transradial angioplasty for ST-elevation myocardial infarction. Interventional Cardiology 3:3, 337-346
CrossRef82
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef83
George D. Dangas, Roxana Mehran, Eugenia Nikolsky, Bimmer E. Claessen, Alexandra J. Lansky, Bruce R. Brodie, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Dariusz Dudek, Martin Möckel, Adriano Caixeta, Helen Parise, Harvey White, Gregg W. Stone. (2011) Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology 57:23, 2309-2316
CrossRef84
(2011) Acute Coronary Syndromes: Initial Medical Therapy. ARC and NZRC Guideline 2011. Emergency Medicine Australasia 23:3, 308-311
CrossRef85
N. J. Breet, H. E. Donkersgoed, J. W. Werkum, H. J. Bouman, J. C. Kelder, F. Zijlstra, C. M. Hackeng, J. M. Berg. (2011) Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. Netherlands Heart Journal 19:6, 279-284
CrossRef86
Pascal Vranckx, Marco Valgimigli, Patrick Serruys. (2011) Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. EuroIntervention 7:2, 263-269
CrossRef87
Roxana Mehran, Stuart Pocock, Eugenia Nikolsky, George D. Dangas, Tim Clayton, Bimmer E. Claessen, Adriano Caixeta, Frederick Feit, Steven V. Manoukian, Harvey White, Michel Bertrand, E. Magnus Ohman, Helen Parise, Alexandra J. Lansky, A. Michael Lincoff, Gregg W. Stone. (2011) Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 4:6, 654-664
CrossRef88
J.-J. Monsuez, H. Belbachir, A. Mahiou, K. Errhamouni, K. Tonyiga. (2011) Les traitements associés à la reperfusion des syndromes coronaires aigus avec sus-décalage de ST. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:199, 31-41
CrossRef89
Martial Hamon, Shamir Mehta, Ph. Gabriel Steg, David Faxon, Prafulla Kerkar, Hans-Jürgen Rupprecht, Jean-François Tanguay, Rizwan Afzal, Salim Yusuf. (2011) Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. EuroIntervention 7:1, 91-97
CrossRef90
Zafar Iqbal, Marc Cohen. (2011) Enoxaparin: a pharmacologic and clinical review. Expert Opinion on Pharmacotherapy 12:7, 1157-1170
CrossRef91
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef92
Davide Capodanno, Corrado Tamburino, George Dangas. (2011) The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 12:7, 1075-1086
CrossRef93
Stefano Savonitto, Nuccia Morici. (2011) Bivalirudina como anticoagulante durante intervenciones coronarias percutáneas en síndromes coronarios agudos: fortalezas y dudas. Revista Española de Cardiología 64:5, 361-364
CrossRef94
Phillip R. Anderson, Prospero B. Gogo, Bina Ahmed, Faye Straight, Edward F. Terrien, Matthew W. Watkins, Nader El Gharib, Harold L. Dauerman. (2011) Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction. Journal of Thrombosis and Thrombolysis 31:4, 401-406
CrossRef95
ROBERT P. GIUGLIANO, CHARLES V POLLACK Jr., GERARD X BROGAN Jr., MARC COHEN, DEBORAH B DIERCKS, CINDY L GRINES, TIMOTHY D. HENRY, NEAL S KLEIMAN. (2011) Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology 24:2, 119-136
CrossRef96
Philippe Kolh, William Wijns. (2011) Joint ESC/EACTS guidelines on myocardial revascularization. Journal of Cardiovascular Medicine 12:4, 264-267
CrossRef97
T. Höchtl, S. Farhan, J. Wojta, K. Huber. (2011) Einsatz von neuen Antikoagulanzien bei kardiovaskulären Erkrankungen. Der Kardiologe 5:2, 129-144
CrossRef98
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2011) Anticoagulant Agents in Acute Coronary Syndromes. Current Problems in Cardiology 36:4, 127-168
CrossRef99
Tzu-Hsien Tsai, Sarah Chua, Hisham Hussein, Steve Leu, Chiung-Jen Wu, Chi-Ling Hang, Hsiu-Yu Fang, Sheng-Ying Chung, Morgan Fu, Huang-Chung Chen, Li-Teh Chang, Kuo-Ho Yeh, Hon-Kan Yip. (2011) Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention*. Critical Care Medicine 39:3, 436-442
CrossRef100
C. Michael Gibson, Akiko Maehara, Alexandra J. Lansky, Jochen Wohrle, Tom Stuckey, Rajesh Dave, David Cox, Cindy Grines, Dariusz Dudek, Gabriel Steg, Helen Parise, Steven D. Wolff, Ecaterina Cristea, Gregg W. Stone. (2011) Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 161:3, 478-486.e7
CrossRef101
Gentian Denas, Vittorio Pengo. (2011) Emerging anticoagulants. Expert Opinion on Emerging Drugs 16:1, 31-44
CrossRef102
Santiago Garcia, Timothy D. Henry, Yale L. Wang, Ivan J. Chavez, Wesley R. Pedersen, John R. Lesser, Gautam R. Shroff, Luke Moore, Jay H. Traverse. (2011) Long-term Follow-up of Patients Undergoing Postconditioning During ST-Elevation Myocardial Infarction. Journal of Cardiovascular Translational Research 4:1, 92-98
CrossRef103
Freek W.A. Verheugt, Steven R. Steinhubl, Martial Hamon, Harald Darius, Philippe Gabriel Steg, Marco Valgimigli, Steven P. Marso, Sunil V. Rao, Anthony H. Gershlick, A. Michael Lincoff, Roxana Mehran, Gregg W. Stone. (2011) Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 4:2, 191-197
CrossRef104
Charles L. Campbell, Steven R. Steinhubl, William C. Hooper, Joseph Jozic, Susan S. Smyth, Debra Bernstein, Christine Staercke, George Syros, Brian H. Negus, Thomas Stuckey, Gregg W. Stone, Roxana Mehran, George Dangas. (2011) Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. Journal of Thrombosis and Thrombolysis 31:2, 139-145
CrossRef105
Sanjit S. Jolly, Kari Niemelä, Denis Xavier, Petr Widimsky, Andrzej Budaj, Vicent Valentin, Basil S. Lewis, Alvaro Avezum, Philippe Gabriel Steg, Sunil V. Rao, John Cairns, Susan Chrolavicius, Salim Yusuf, Shamir R. Mehta. (2011) Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal 161:2, 254-260.e4
CrossRef106
Adriano Caixeta, George D. Dangas, Roxana Mehran, Frederick Feit, Eugenia Nikolsky, Alexandra J. Lansky, Jiro Aoki, Jeffrey W. Moses, Steven R. Steinhubl, Harvey D. White, E. Magnus Ohman, Steven V. Manoukian, Martin Fahy, Gregg W. Stone. (2011) Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 161:2, 298-306.e1
CrossRef107
Eltigani Abdelaal, Jonathan Byrne. (2011) Bleeding avoidance strategies among patients undergoing percutaneous coronary intervention. Interventional Cardiology 3:1, 13-16
CrossRef108
Sandhir B. Prasad, Thomas David, Yuvaraj Malaiapan, James D. Cameron, Ian T. Meredith. (2011) Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: Rationale and safety. Catheterization and Cardiovascular Interventions 77:2, 193-200
CrossRef109
Serafina Valente, Chiara Lazzeri, Marco Chiostri, Lusinda Osmanagaj, Cristina Giglioli, Gian Franco Gensini. (2011) STEMI Patients-The More You Bleed, the More You Die: A Comparison Between Classifications. Clinical Cardiology 34:2, 90-96
CrossRef110
Thomas J. Povsic, Mauricio G. Cohen, Roxana Mehran, Christopher E. Buller, Christoph Bode, Jan H. Cornel, Jarosław D. Kasprzak, Gilles Montalescot, Diane Joseph, William A. Wargin, Christopher P. Rusconi, Steven L. Zelenkofske, Richard C. Becker, John H. Alexander. (2011) A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. American Heart Journal 161:2, 261-268.e2
CrossRef111
Ivan C. Rokos, Michael E. Farkouh, James Reiffel, Ovidiu Dressler, Roxana Mehran, Gregg W. Stone. (2011) Correlation between index electrocardiographic patterns and Pre-intervention angiographic findings: Insights from the HORIZONS-AMI trial. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef112
Dongmei Zhang, Zining Wang, Xia Zhao, Wei Lu, Jingkai Gu, Yimin Cui. (2011) Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Single Doses of Bivalirudin in Healthy Chinese Subjects. Biological & Pharmaceutical Bulletin 34:12, 1841-1848
CrossRef113
Kugathasan Nadarasa, M. Clare Robertson, Cheuk-Kit Wong, Belinda K.W. Green, Victor H.T. Chen, Gerard T. Wilkins, Michael J.A. Williams. (2011) Rapid cycle change to predominantly radial access coronary angiography and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef114
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef115
Nicholas Collins, Rodrigo Wainstein, Michael Ward, Rohan Bhagwandeen, Vladimir Dzavik. (2011) Pseudoaneurysm after transradial cardiac catheterization: Case series and review of the literature. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef116
Olivier Barthélémy, Johanne Silvain, David Brieger, Anne Mercadier, Remi Lancar, Anne Bellemain-Appaix, Farzin Beygui, Jean Philippe Collet, Dominique Costagliola, Gilles Montalescot. (2011) Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. Catheterization and Cardiovascular Interventions 79:1, 104-112
CrossRef117
R. S. Hermanides, J. P. Ottervanger, J.-H. E. Dambrink, M.-J. de Boer, J. C. A. Hoorntje, A. T. M. Gosselink, H. Suryapranata, F. Zijlstra, A. W. J. van ‘t Hof, . (2011) Suboptimal anticoagulation with pre-hospital heparin in ST-elevation myocardial infarction. Thrombosis and Haemostasis 106:4, 636-640
CrossRef118
Koyu Sakai, Shinya Nagayama, Kasumi Ihara, Kenji Ando, Shinichi Shirai, Katsuhiro Kondo, Hiroyoshi Yokoi, Masashi Iwabuchi, Hideyuki Nosaka, Masakiyo Nobuyoshi. (2011) Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥75 years. Catheterization and Cardiovascular Interventions 79:1, 50-56
CrossRef119
Matthias Schwenkglenks, John E. Brazier, Thomas D. Szucs, Keith A.A. Fox. (2011) Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes. Value in Health 14:1, 24-33
CrossRef120
José Luis Ferreiro, Joan Antoni Gómez-Hospital, Dominick J. Angiolillo, Ángel Cequier. (2011) ¿Los nuevos antagonistas del receptor P2Y12 pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. Revista Española de Cardiología Suplementos 11, 14-19
CrossRef121
David P. Faxon. (2011) Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef122
David E. Winchester, William D. Brearley, Xuerong Wen, Ki E. Park, Anthony A. Bavry. (2011) Efficacy and Safety of Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Revascularization for an Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials Performed With Stents and Thienopyridines. Clinical Cardiologyn/a-n/a
CrossRef123
H. Benamer, B. Meftout, B. Chevalier. (2010) Le risque de saignement dans les syndromes coronariens aigus avec sus-décalage du segment ST. Annales de Cardiologie et d'Angéiologie 59:6, 356-361
CrossRef124
P. Aubry, X. Halna du Fretay. (2010) Traitements antithrombotiques du syndrome coronarien aigu avec sus-décalage ST. Annales de Cardiologie et d'Angéiologie 59:6, 335-343
CrossRef125
ANGELA MIGLIORINI, RENATO VALENTI, GUIA MOSCHI, GUIDO PARODI, GIAMPAOLO CERISANO, PIERGIOVANNI BUONAMICI, NAZARIO CARRABBA, DAVID ANTONIUCCI. (2010) Predictor of Stent Thrombosis in Patients Treated with Turbostratic Carbon-Coated Stent Implantation for Acute Myocardial Infarction. Journal of Interventional Cardiology 23:6, 554-559
CrossRef126
Elias B. Hanna, Sunil V. Rao, Steven V. Manoukian, Jorge F. Saucedo. (2010) The Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:12, 1209-1219
CrossRef127
Bimmer Claessen, Roxana Mehran, Gregg W Stone. (2010) Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. Interventional Cardiology 2:6, 757-759
CrossRef128
V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
CrossRef129
S. Silber. (2010) Evidenzbasiertes Vorgehen beim ST-Strecken-Hebungsinfarkt (STEMI). Herz 35:8, 558-565
CrossRef130
Ralf Birkemeyer, Andreas Rillig, Annette Koch, Tomislav Miljak, Markus Kunze, Udo Meyerfeldt, Wolfgang Steffen, Martin Soballa, Carsten Ranke, Roland Prassler, Albert Benzing, Werner Jung. (2010) Primary angioplasty for any patient with ST-elevation myocardial infarction? Guideline-adherent feasibility and impact on mortality in a rural infarction network. Clinical Research in Cardiology 99:12, 833-840
CrossRef131
Stefanie Schulz, K. Anette Birkmeier, Gjin Ndrepepa, Werner Moshage, Franz Dotzer, Kurt Huber, Josef Dirschinger, Melchior Seyfarth, Albert Schömig, Adnan Kastrati, Julinda Mehilli. (2010) One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clinical Research in Cardiology 99:12, 795-802
CrossRef132
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef133
Mitul B. Kadakia, Nihar R. Desai, Karen P. Alexander, Anita Y. Chen, JoAnne M. Foody, Christopher P. Cannon, Stephen D. Wiviott, Benjamin M. Scirica. (2010) Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction. JACC: Cardiovascular Interventions 3:11, 1166-1177
CrossRef134
H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms. Notfall + Rettungsmedizin 13:7, 621-634
CrossRef135
Shoaib Amlani, Thanu Nadarajah, Rizwan Afzal, Renu Pal-Sayal, John W. Eikelboom, Madhu K. Natarajan. (2010) Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. Journal of Thrombosis and Thrombolysis 30:4, 434-440
CrossRef136
Paul W. Armstrong, Robert C. Welsh. (2010) Rear-View Mirror Observations on Bleeding in Acute Coronary Syndromes. JACC: Cardiovascular Interventions 3:11, 1178-1180
CrossRef137
Venkatesan D. Vidi, Michael E. Matheny, Vikram Agarwal, Nipun Arora, Sharon Donnelly, Sripal Bangalore, Frederic S. Resnic. (2010) Validation of Long-Term Benefits of Bivalirudin Versus Unfractionated Heparin in Routine Clinical Practice After Percutaneous Coronary Intervention. The American Journal of Cardiology 106:9, 1234-1240
CrossRef138
A. A. C. M. HEESTERMANS, J. W. VAN WERKUM, B. ZWART, J. A. VAN DER HEYDEN, J. C. KELDER, N. J. BREET, A. W. J. VAN'T HOF, J.-H. E. DAMBRINK, J. J. KOOLEN, B. R. G. BRUEREN, F. ZIJLSTRA, J. M. TEN BERG. (2010) Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. Journal of Thrombosis and Haemostasis 8:11, 2385-2393
CrossRef139
A.A.C.M. Heestermans, R.S. Hermanides, A.T.M. Gosselink, M.J. Boer, J.C.A. Hoorntje, H. Suryapranata, J.P. Ottervanger, J-H.E. Dambrink, E. Kolkman, J.M. Berg, F. Zijlstra, A.W.J. Hof. (2010) A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI. Netherlands Heart Journal 18:12, 592-597
CrossRef140
Jochen Wöhrle, Martin Desaga, Chris Metzger, Kurt Huber, Harry Suryapranata, Victor Guetta, Giulio Guagliumi, Bernhard Witzenbichler, Helen Parise, Roxana Mehran, Gregg W. Stone. (2010) Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). The American Journal of Cardiology 106:9, 1218-1224
CrossRef141
Hans D. Theiss, Christoph Brenner, Markus G. Engelmann, Marc-Michael Zaruba, Bruno Huber, Volkmar Henschel, Ulrich Mansmann, Bernd Wintersperger, Maximilian Reiser, Gerhard Steinbeck, Wolfgang-M. Franz. (2010) Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis. International Journal of Cardiology 145:2, 282-284
CrossRef142
S. Schulz, J. Mehilli, F.-J. Neumann, T. Schuster, S. Massberg, C. Valina, M. Seyfarth, J. Pache, K.-L. Laugwitz, H.-J. Buttner, G. Ndrepepa, A. Schomig, A. Kastrati, . (2010) ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European Heart Journal 31:20, 2482-2491
CrossRef143
, , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
CrossRef144
H. M. Nef, H. Mollmann, C. W. Hamm. (2010) Anticoagulation in percutaneous coronary interventions: no man's land?. European Heart Journal 31:20, 2447-2448
CrossRef145
Warren Kyle Stribling, Antonio Abbate, Michael Kontos, George W Vetrovec, Kapildeo Lotun. (2010) Myocardial infarctions involving acute left circumflex occlusion: are all occlusions created equally?. Interventional Cardiology 2:5, 695-704
CrossRef146
Matthew A. Cavender, Sunil V. Rao. (2010) Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?. Journal of Thrombosis and Thrombolysis 30:3, 332-339
CrossRef147
Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
CrossRef148
Leo Bossaert, Robert E. O’Connor, Hans-Richard Arntz, Steven C. Brooks, Deborah Diercks, Gilson Feitosa-Filho, Jerry P. Nolan, Terry L. Vanden Hoek, Darren L. Walters, Aaron Wong, Michelle Welsford, Karen Woolfrey. (2010) Part 9: Acute coronary syndromes. Resuscitation 81:1, e175-e212
CrossRef149
Zafar Iqbal, Marc Cohen. (2010) Emerging antithrombotic agents: what does the intensivist need to know?. Current Opinion in Critical Care 16:5, 419-425
CrossRef150
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu Wong. (2010) Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheterization and Cardiovascular Interventions 76:4, 513-524
CrossRef151
Hiroshi Doi, Akiko Maehara, Gary S. Mintz, Kenichi Tsujita, Takashi Kubo, Celia Castellanos, Alexandra J. Lansky, Bernhard Witzenbichler, Giulio Guagliumi, Bruce Brodie, Mirle A. Kellett, Helen Parise, Roxana Mehran, Martin B. Leon, Jeffrey W. Moses, Gregg W. Stone. (2010) Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. The American Journal of Cardiology 106:7, 952-957
CrossRef152
Dinesh Kumar, George Dangas, Roxana Mehran, Ajay Kirtane, Michel Bertrand, Ramin Ebrahimi, Giulio Guagliumi, Somjot Brar, Martin Fahy, Eric Heller, Jeffrey Moses, Gregg Stone. (2010) Comparison of Bivalirudin Versus Bivalirudin Plus Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Having Percutaneous Intervention for Narrowed Saphenous Vein Aorto-Coronary Grafts (the ACUITY Trial Investigators). The American Journal of Cardiology 106:7, 941-945
CrossRef153
John J. Lopez, Michelle J. Keyes, Sandeep Nathan, Robert Piana, Michael Pencina, Gaurav Dhar, Steven Marso, Sunil Rao, Salim Shammo, Walt Marquardt, David J. Cohen, Neal S. Kleiman. (2010) Rapid adoption of drug-eluting stents: Clinical practices and outcomes from the early drug-eluting stent era. American Heart Journal 160:4, 767-774.e1
CrossRef154
Xavier Bosch, Jaume Marrugat, Juan Sanchis, Xavier Bosch. 2010. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef155
Mauricio G. Cohen. (2010) Intracoronary Thrombus. JACC: Cardiovascular Interventions 3:9, 947-949
CrossRef156
Manivannan Srinivasan, Charanjit S. Rihal, Mandeep Singh, Ryan J. Lennon, David R. Holmes, Abhiram Prasad. (2010) Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus. JACC: Cardiovascular Interventions 3:9, 937-946
CrossRef157
R. P. Giugliano, R. R. Giraldez, D. A. Morrow, E. M. Antman, C. M. Gibson, S. Mohanavelu, S. A. Murphy, C. H. McCabe, E. Braunwald. (2010) Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. European Heart Journal 31:17, 2103-2110
CrossRef158
D. A. Morrow, E. M. Antman, K. A. A. Fox, H. D. White, R. Giugliano, S. A. Murphy, C. H. McCabe, E. Braunwald, . (2010) One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. European Heart Journal 31:17, 2097-2102
CrossRef159
Srinivas Iyengar, LeRoy E Rabbani. (2010) Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: Drug-Eluting Stents or Bare Metal Stents?. American Journal of Therapeutics 17:5, 516-522
CrossRef160
Deepak Thomas, Robert P. Giugliano. (2010) Perspectives on the 2009 Focused Updates on the Management of ST-Segment Elevation Myocardial Infarction and Percutaneous Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:3, 126-133
CrossRef161
Omar Ait Mokhtar, Gilles Lemesle, Sébastien Armero, Julien Mancini, Caroline Bonello, Iliassou Tahirou, Paul Barragan, Françoise Dignat-George, Laurence Camoin-Jau, Franck Paganelli, Laurent Bonello. (2010) Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thrombosis Research 126:2, e147-e149
CrossRef162
Brian P O’Neill, Eric Scot Shaw, Mauricio G Cohen. (2010) Anticoagulation in percutaneous coronary intervention. Interventional Cardiology 2:4, 559-577
CrossRef163
H. Thiele, B. Allam, G. Chatellier, G. Schuler, A. Lafont. (2010) Shock in acute myocardial infarction: the Cape Horn for trials?. European Heart Journal 31:15, 1828-1835
CrossRef164
Guido Parodi, David Antoniucci, Eugenia Nikolsky, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Thomas Stuckey, Darius Dudek, Ran Kornowski, Franz Hartmann, Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone. (2010) Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions 3:8, 796-802
CrossRef165
Tobias Geisler, Meinrad Gawaz, Steven R. Steinhubl, Deepak L. Bhatt, Robert F. Storey, Marcus Flather. (2010) Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. Pharmacology & Therapeutics 127:2, 95-107
CrossRef166
Pier Mannuccio Mannucci, Massimo Franchini. (2010) Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. European Journal of Internal Medicine 21:4, 254-259
CrossRef167
Zbigniew Siudak, Barbara Zawislak, Artur Dziewierz, Tomasz Rakowski, Jacek Jakala, Stanislaw Bartus, Beata Noworolnik, Wojciech Zasada, Jacek S. Dubiel, Dariusz Dudek. (2010) Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry. Coronary Artery Disease 21:5, 292-297
CrossRef168
Fernando Alfonso, Manuel Paulo. (2010) Bivalirudin in Acute Myocardial Infarction: “Primum Non Nocere”. JACC: Cardiovascular Interventions 3:8, 803-805
CrossRef169
Michael S. Lee, Pooya Bokhoor, Seung-Jung Park, Young-Hak Kim, Gregg W. Stone, Imad Sheiban, Giuseppe Biondi-Zoccai, Dario Sillano, Jonathan Tobis, David E. Kandzari. (2010) Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:8, 791-795
CrossRef170
Dabit Arzamendi, Hung Quoc Ly, Jean-François Tanguay, Mark Yan Yee Chan, Pierre Chevallereau, Richard Gallo, Reda Ibrahim, Philippe L'Allier, Sylvie Levesque, Gilbert Gosselin, Pierre DeGuise, Michel Joyal, Jean Gregoire, Raoul Bonan, Jacques Crepeau, Serge Doucet. (2010) Effect on Bleeding, Time to Revascularization, and One-Year Clinical Outcomes of the Radial Approach During Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology 106:2, 148-154
CrossRef171
Bruce R. Brodie, Bernard J. Gersh, Thomas Stuckey, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Dariusz Dudek, Cindy L. Grines, David Cox, Helen Parise, Abhiram Prasad, Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone. (2010) When Is Door-to-Balloon Time Critical?. Journal of the American College of Cardiology 56:5, 407-413
CrossRef172
Dmitriy N. Feldman, S. Chiu Wong. (2010) Reply. The American Journal of Cardiology 106:1, 140-141
CrossRef173
Arnold H. Seto, Mazen S. Abu-Fadel, Jeffrey M. Sparling, Soni J. Zacharias, Timothy S. Daly, Alexander T. Harrison, William M. Suh, Jesus A. Vera, Christopher E. Aston, Rex J. Winters, Pranav M. Patel, Thomas A. Hennebry, Morton J. Kern. (2010) Real-Time Ultrasound Guidance Facilitates Femoral Arterial Access and Reduces Vascular Complications. JACC: Cardiovascular Interventions 3:7, 751-758
CrossRef174
Gjin Ndrepepa, Dritan Keta, Stefanie Schulz, Julinda Mehilli, Anette Birkmeier, Franz-Josef Neumann, Albert Schömig, Adnan Kastrati. (2010) Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. Heart and Vessels 25:4, 294-298
CrossRef175
Yee W Wong, Roshan Prakash, Derek P Chew. (2010) Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology 25:4, 305-311
CrossRef176
Amit P. Amin, Steven P. Marso. (2010) Acute Coronary Syndrome in the Patient with Diabetes: Is the Management Different?. Current Cardiology Reports 12:4, 321-329
CrossRef177
G. Y. H. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen, T. Cuisset, P. Kirchhof, F. Marin. (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 31:11, 1311-1318
CrossRef178
Nihar R. Desai, Deepak L. Bhatt. (2010) The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC: Cardiovascular Interventions 3:6, 571-583
CrossRef179
Michael Koutouzis, Per Albertsson. (2010) Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction. Acute Cardiac Care 12:2, 75-76
CrossRef180
Rhidian J. Shelton, Andrew M. Crean, Kathryn Somers, Claire Priestley, Carol Hague, Jonathan M. Blaxill, Stephen B. Wheatcroft, James M. McLenachan, John P. Greenwood, Daniel J. Blackman. (2010) Real-world outcome from ST elevation myocardial infarction in the very elderly before and after the introduction of a 24/7 primary percutaneous coronary intervention service. American Heart Journal 159:6, 956-963
CrossRef181
Roxana Mehran, Stuart J. Pocock, Eugenia Nikolsky, Tim Clayton, George D. Dangas, Ajay J. Kirtane, Helen Parise, Martin Fahy, Steven V. Manoukian, Frederick Feit, Magnus E. Ohman, Bernard Witzenbichler, Giulio Guagliumi, Alexandra J. Lansky, Gregg W. Stone. (2010) A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 55:23, 2556-2566
CrossRef182
CEDRIC DELHAYE, KOHEI WAKABAYASHI, GABRIEL MALUENDA, ITSIK BEN-DOR, REBECCA TORGUSON, ZHENYI XUE, WILLIAM O. SUDDATH, LOWELL F. SATLER, AUGUSTO D. PICHARD, KENNETH M. KENT, JOSEPH LINDSAY, RON WAKSMAN. (2010) Safety and Efficacy of Bivalirudin for Percutaneous Coronary Intervention with Rotational Atherectomy. Journal of Interventional Cardiology 23:3, 223-229
CrossRef183
Jeffrey Brinker. (2010) The Score Is in but Is the Decision Final?
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 55:23, 2567-2569
CrossRef184
Timm Bauer, Uwe Zeymer. (2010) Impact of age on outcomes of percutaneous coronary intervention in acute coronary syndromes patients. Interventional Cardiology 2:3, 319-325
CrossRef185
Michael Koutouzis, Lars Grip. (2010) Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Interventional Cardiology 2:3, 301-318
CrossRef186
Cédric Delhaye, Kohei Wakabayashi, Gabriel Maluenda, Loic Belle, Itsik Ben-Dor, Manuel A. Gonzalez, Michael A. Gaglia, Rebecca Torguson, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2010) Body mass index and bleeding complications after percutaneous coronary intervention: Does bivalirudin make a difference?. American Heart Journal 159:6, 1139-1146
CrossRef187
Monique P. Curran. (2010) Bivalirudin. Drugs 70:7, 909-918
CrossRef188
A. De Labriolle, L. Bonello, G. Lemesle, P. Roy, D. H. Steinberg, Z. Xue, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard, J. Lindsay, R. Waksman. (2010) Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors. European Heart Journal 31:9, 1079-1087
CrossRef189
Somjot S Brar, Gregg W Stone. (2010) Decision-making: stenting in acute myocardial infarction. Future Cardiology 6:3, 301-314
CrossRef190
Thomas Cuisset, Marco Valgimigli, Harald Mudra, Olivier Muller, William Wijns, Kurt Huber. (2010) Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention 6:1, 39-45
CrossRef191
S. Michael Gharacholou, Renato D. Lopes, Jeffrey B. Washam, L. Kristin Newby, Stefan K. James, John H. Alexander. (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 29:4, 516-528
CrossRef192
KENICHI TSUJITA, AKIKO MAEHARA, GARY S. MINTZ, ALEXANDRA J. LANSKY, TAKASHI KUBO, HIROSHI DOI, JUNQING YANG, HARPREET BHARAJ, BERNHARD WITZENBICHLER, GIULIO GUAGLIUMI, BRUCE R. BRODIE, MIRLE A. KELLETT, HELEN PARISE, ROXANA MEHRAN, GREGG W. STONE. (2010) Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. Journal of Interventional Cardiology 23:2, 114-122
CrossRef193
Michael Koutouzis, Göran Matejka, Göran Olivecrona, Lars Grip, Per Albertsson. (2010) Radial vs. femoral approach for primary percutaneous coronary intervention in octogenarians. Cardiovascular Revascularization Medicine 11:2, 79-83
CrossRef194
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef195
José G. Díez, James M. Wilson. (2010) Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory. Cardiovascular Drugs and Therapy 24:2, 161-174
CrossRef196
Holger Thiele, Jochen Wöhrle, Petra Neuhaus, Oana Brosteanu, Peter Sick, Roland Prondzinsky, Ralf Birkemeyer, Marcus Wiemer, Sebastian Kerber, Helmut Schuehlen, Klaus Kleinertz, Christoph Axthelm, Rainer Zimmermann, Harald Rittger, Rüdiger C. Braun-Dullaeus, Bernward Lauer, Wolfgang Burckhardt, Markus Ferrari, Martin W. Bergmann, Rainer Hambrecht, Gerhard Schuler. (2010) Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. American Heart Journal 159:4, 547-554
CrossRef197
, T. Lickfeld, C. Hamm, M. Möckel, J. Vollert, M. Haude. (2010) Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. Der Kardiologe 4:2, 107-123
CrossRef198
Bina Ahmed, Colleen Thomas, Carl Kapadia, Faraz Sandhu, Sadie Mills, Faye Straight, David J. Schneider, Harold L. Dauerman. (2010) Frequency and safety of switching antithrombin therapy at a regional PCI center. Journal of Thrombosis and Thrombolysis 29:3, 282-288
CrossRef199
J.-P. Bassand. (2010) A reduction in bleeding in acute coronary syndromes? Let's not rain on the parade!. European Heart Journal 31:6, 640-641
CrossRef200
Michael Koutouzis, Lars Grip, Göran Matejka, Per Albertsson. (2010) Primary Percutaneous Coronary Interventions in Nonagenarians. Clinical Cardiology 33:3, 157-161
CrossRef201
S. S. Jolly, S. Yusuf. (2010) Which antithrombotic to use during PCI?. European Heart Journal 31:5, 522-524
CrossRef202
S. Schulz, J. Mehilli, G. Ndrepepa, F.-J. Neumann, K. A. Birkmeier, S. Kufner, G. Richardt, P. B. Berger, A. Schomig, A. Kastrati, . (2010) Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. European Heart Journal 31:5, 582-587
CrossRef203
Amar Krishnaswamy, A. Michael Lincoff, Christopher P. Cannon. (2010) The Use and Limitations of Unfractionated Heparin. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:1, 35-40
CrossRef204
J. A. Rassen, M. A. Mittleman, R. J. Glynn, M. Alan Brookhart, S. Schneeweiss. (2010) Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. European Heart Journal 31:5, 561-572
CrossRef205
Marc Cohen. (2010) The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials. The American Journal of Medicine 123:2, 103-110
CrossRef206
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef207
Jon C. George, George D. Dangas. (2010) 2009 Focused Updates to Guidelines in ST-Elevation Myocardial Infarction and Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:2, 256-258
CrossRef208
Gilles Montalescot, Stephen G. Ellis, Mark A. de Belder, Luc Janssens, Olivier Katz, Wladyslaw Pluta, Patrick Ecollan, Michal Tendera, Ad J. van Boven, Petr Widimsky, Henning R. Andersen, Amadeo Betriu, Paul Armstrong, Bruce R. Brodie, Howard C. Herrmann, Franz-Josef Neumann, Mark B. Effron, Jiandong Lu, Elliot S. Barnathan, Eric J. Topol. (2010) Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:2, 203-212
CrossRef209
Shaun G. Goodman. (2010) Does Enoxaparin Have Enough FINESSE to Replace Unfractionated Heparin in Primary Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions 3:2, 213-214
CrossRef210
Cedric Delhaye, Gabriel Maluenda, Kohei Wakabayashi, Itsik Ben-Dor, Sara D. Collins, Asmir I. Syed, Manuel A. Gonzalez, Michael A. Gaglia, Rebecca Torguson, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2010) Safety and In-Hospital Outcomes of Bivalirudin Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention. The American Journal of Cardiology 105:3, 297-301
CrossRef211
Gregg W. Stone, Stuart J. Pocock. (2010) Randomized Trials, Statistics, and Clinical Inference. Journal of the American College of Cardiology 55:5, 428-431
CrossRef212
D. SIBBING, S. SCHULZ, S. BRAUN, T. MORATH, J. STEGHERR, J. MEHILLI, A. SCHÖMIG, N. VON BECKERATH, A. KASTRATI. (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis 8:2, 250-256
CrossRef213
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef214
Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet 375:9711, 283-293
CrossRef215
Rajendra H. Mehta, Renato D. Lopes, Andrea Ballotta, Alessandro Frigiola, Michael H. Sketch, Eduardo Bossone, Eric R. Bates. (2010) Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?. American Heart Journal 159:1, 141-147
CrossRef216
Rosa-Maria Lidón. (2010) Tratamiento anticoagulante en el síndrome coronario agudo. Reflexiones sobre su estado actual. Revista Española de Cardiología Suplementos 10:4, 3D-11D
CrossRef217
Harvey D. White, Philip E. Aylward, Richard Gallo, Christoph Bode, Gabriel Steg, Steven R. Steinhubl, Gilles Montalescot. (2010) Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. American Heart Journal 159:1, 110-116
CrossRef218
Alois Suessenbacher, Maria M. Wanitschek, Jakob Doerler, Otmar Pachinger, Hannes F. Alber. (2010) STEMI-Guidelines 2008 – Konsequenzen für die heutige Infarktversorgung im ländlichen Raum?. Wiener Medizinische Wochenschrift 160:1-2, 54-60
CrossRef219
Gregg W Stone. (2010) Ticagrelor in ACS: redefining a new standard of care?. The Lancet 375:9711, 263-265
CrossRef220
Allen Jeremias, Sujethra Vasu, Luis Gruberg, Adnan Kastrati, Gregg W. Stone, David L. Brown. (2010) Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef221
Gjin Ndrepepa, Stefanie Schulz, Dritan Keta, Julinda Mehilli, Anette Birkmeier, Steffen Massberg, Karl-Ludwig Laugwitz, Franz-Josef Neumann, Melchior Seyfarth, Peter B. Berger, Albert Schömig, Adnan Kastrati. (2010) Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. The American Journal of Cardiology 105:2, 163-167
CrossRef222
Sandhir B. Prasad, Walid Ahmar, Yuvaraj Malaiapan, Ian T. Meredith. (2010) Drug-eluting Stents for the Treatment of Acute Myocardial Infarction: The View to the HORIZONS. Heart, Lung and Circulation 19:1, 11-18
CrossRef223
Sunil V. Rao. (2010) Hemorragia en pacientes con síndromes coronarios agudos: de un hallazgo molesto a un reto importante. Revista Española de Cardiología 63:1, 1-4
CrossRef224
Roy Beinart, Raed Abu Sham'a, Amit Segev, Hanoch Hod, Victor Guetta, Michael Shechter, Valentina Boyko, Shlomo Behar, Shlomi Matetzky. (2010) The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome. American Heart Journal 159:1, 118-124
CrossRef225
Stefanie Schulz, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2010) ISAR. Circulation Journal 74:9, 1771-1778
CrossRef226
Marc Bonaca, Robert P. Giugliano. (2010) Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine 12:1, 84-99
CrossRef227
Sunil V. Rao, John Eikelboom, Ph. Gabriel Steg, A. Michael Lincoff, William S. Weintraub, Jean-Pierre Bassand, A. Koneti Rao, C. Michael Gibson, John L. Petersen, Roxana Mehran, Steven V. Manoukian, Richard Charnigo, Kerry L. Lee, Mauro Moscucci, Robert A. Harrington. (2009) Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal 158:6, 881-886.e1
CrossRef228
Nader Z. Elgharib, Umang H. Shah, John T. Coppola. (2009) Transradial cardiac catheterization and percutaneous coronary intervention: a review. Coronary Artery Disease 20:8, 487-493
CrossRef229
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
CrossRef230
P. K. Kong, D. Connolly, C. Varma, G. Lip, T. Millane, R. Davis, R. Ahmad. (2009) High-risk myocardial infarction patients appear to derive more mortality benefit from short door-to-balloon time than low-risk patients. International Journal of Clinical Practice 63:12, 1693-1701
CrossRef231
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
CrossRef232
Gabriel Maluenda, Gilles Lemesle, Sara D. Collins, Itsik Ben-Dor, Asmir I. Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, Rajbabu Pakala, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2009) The clinical significance of hematocrit values before and after percutaneous coronary intervention. American Heart Journal 158:6, 1024-1030
CrossRef233
G. De Luca, E. Navarese, P. Marino. (2009) Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. European Heart Journal 30:22, 2705-2713
CrossRef234
Davide Tavano, Gabriella Visconti, Davide D'Andrea, Amelia Focaccio, Bruno Golia, Mariateresa Librera, Mario Caccavale, Bruno Ricciarelli, Carlo Briguori. (2009) Comparison of Bivalirudin Monotherapy Versus Unfractionated Heparin Plus Tirofiban in Patients With Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention. The American Journal of Cardiology 104:9, 1222-1228
CrossRef235
Chiara Melloni, Ian Fier, James Roach, Andrzej S. Kosinski, Samuel Broderick, Kristina Sigmon, Shelley Myles, Richard C. Becker, Sunil V. Rao. (2009) Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. American Heart Journal 158:5, 726-733
CrossRef236
Deepak Thomas, Robert P. Giugliano. (2009) Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal 158:5, 695-705
CrossRef237
Amar Krishnaswamy, A. Michael Lincoff, Venu Menon. (2009) Magnitude and consequences of missing the acute infarct-related circumflex artery. American Heart Journal 158:5, 706-712
CrossRef238
Payam Dehghani, Atif Mohammad, Ravi Bajaj, Tony Hong, Colin M. Suen, Waseem Sharieff, Robert J. Chisholm, Michael J.B. Kutryk, Neil P. Fam, Asim N. Cheema. (2009) Mechanism and Predictors of Failed Transradial Approach for Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions 2:11, 1057-1064
CrossRef239
Jason B. Lindsey, Steven P. Marso, Michael Pencina, Joshua M. Stolker, Kevin F. Kennedy, Charanjit Rihal, Greg Barsness, Robert N. Piana, Steven L. Goldberg, Donald E. Cutlip, Neal S. Kleiman, David J. Cohen. (2009) Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients. JACC: Cardiovascular Interventions 2:11, 1074-1082
CrossRef240
Amit Kumar, Christopher P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part II. Mayo Clinic Proceedings 84:11, 1021-1036
CrossRef241
E. M. Jolic ur, W. W. O'Neill, A. Hellkamp, C. W. Hamm, D. R. Holmes, H. R. Al-Khalidi, M. R. Patel, F. J. Van de Werf, K. Pieper, P. W. Armstrong, C. B. Granger, . (2009) Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. European Heart Journal 30:21, 2575-2583
CrossRef242
Douglass A. Morrison. (2009) ‘‘They can always hurt you more’’ Bivalirudin and the dynamic balance between bleeding and clotting. Catheterization and Cardiovascular Interventions 74:5, 708-709
CrossRef243
Patrick Goldstein, Frederic Lapostolle, Gabriel Steg, Nicolas Danchin, Nathalie Assez, Gilles Montalescot, Sandrine Charpentier, Eric Wiel, Jean Michel Juliard. (2009) Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. European Journal of Emergency Medicine 16:5, 244-255
CrossRef244
Antonio Manari, Remo Albiero, Stefano De Servi. (2009) High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome?. Journal of Cardiovascular Medicine 10:Suppl 1, S13-S16
CrossRef245
Daniel I. Simon, Sahil A. Parikh. (2009) Hunting for the “Sweet Spot” in P2Y12 Receptor Blockade
CrossRef246
Ranil de Silva, Kim M Fox. (2009) The changing horizon of acute coronary syndrome. The Lancet 374:9696, 1125-1127
CrossRef247
JACOB A. DOLL, EUGENIA NIKOLSKY, GREGG W. STONE, ROXANA MEHRAN, A. MICHAEL LINCOFF, ADRIANO CAIXETA, BRENT MCLAURIN, ECATERINA CRISTEA, MARTIN FAHY, VIJAYA KESANAKURTHY, ALEXANDRA J. LANSKY. (2009) Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE-2, ACUITY, and HORIZONS-AMI Trials. Journal of Interventional Cardiology 22:5, 453-459
CrossRef248
Roxana Mehran, Alexandra J Lansky, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z Peruga, Bruce R Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, Bernard J Gersh, Stuart J Pocock, S Chiu Wong, Eugenia Nikolsky, Louise Gambone, Lynn Vandertie, Helen Parise, George D Dangas, Gregg W Stone. (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 374:9696, 1149-1159
CrossRef249
George Dangas, Roxana Mehran, Giulio Guagliumi, Adriano Caixeta, Bernhard Witzenbichler, Jiro Aoki, Jan Z. Peruga, Bruce R. Brodie, Dariusz Dudek, Ran Kornowski, LeRoy E. Rabbani, Helen Parise, Gregg W. Stone. (2009) Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. Journal of the American College of Cardiology 54:15, 1438-1446
CrossRef250
A. A. C. M. HEESTERMANS, J. W. VAN WERKUM, C. HAMM, T. DILL, A. T. M. GOSSELINK, M. J. DE BOER, G. VAN HOUWELINGEN, J. C. A. HOORNTJE, P. C. KOOPMANS, J. M. TEN BERG, A. W. J. VAN âT HOF. (2009) Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. Journal of Thrombosis and Haemostasis 7:10, 1612-1618
CrossRef251
Bernardo Cortese, Andrea Picchi, Andrea Micheli, Alberto Genovesi Ebert, Francesca Parri, Silva Severi, Ugo Limbruno. (2009) Comparison of Prolonged Bivalirudin Infusion Versus Intraprocedural in Preventing Myocardial Damage After Percutaneous Coronary Intervention in Patients With Angina Pectoris. The American Journal of Cardiology 104:8, 1063-1068
CrossRef252
Mark Y. Chan, Jeffrey I. Weitz, Yahye Merhi, Robert A. Harrington, Richard C. Becker. (2009) Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. Journal of Thrombosis and Thrombolysis 28:3, 366-380
CrossRef253
Stefano Savonitto, Carlo Briguori, Flavio Ribichini, Fabrizio Tomai, Emanuela Piccaluga. (2009) Primary percutaneous coronary intervention: different outcome for different subgroups?. Journal of Cardiovascular Medicine 10:Suppl 1, S27-S34
CrossRef254
John P Vavalle, Sunil V Rao. (2009) Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interventional Cardiology 1:1, 51-62
CrossRef255
Wallentin, Lars, Becker, Richard C., Budaj, Andrzej, Cannon, Christopher P., Emanuelsson, Håkan, Held, Claes, Horrow, Jay, Husted, Steen, James, Stefan, Katus, Hugo, Mahaffey, Kenneth W., Scirica, Benjamin M., Skene, Allan, Steg, Philippe Gabriel, Storey, Robert F., Harrington, Robert A., . (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 361:11, 1045-1057
Full Text256
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef257
Gilles Lemesle, Axel De Labriolle, Laurent Bonello, Asmir Syed, Sara Collins, Gabriel Maluenda, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2009) Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 74:3, 428-435
CrossRef258
Marco De Carlo, Gabriele Borelli, Roberto Gistri, Nicola Ciabatti, Alessandra Mazzoni, Marco Arena, A. Sonia Petronio. (2009) Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes. Catheterization and Cardiovascular Interventions 74:3, 408-415
CrossRef259
Leonardo De Luca, Gianni Casella, Maddalena Lettino, Giuseppe Fradella, Vincenzo Toschi, Maria Rosa Conte, Filippo Ottani, Giovanna Geraci, Luigi O Visconti, Marco Tubaro, Aldo P Maggioni. (2009) Clinical implications and management of bleeding events in patients with acute coronary syndromes. Journal of Cardiovascular Medicine 10:9, 677-686
CrossRef260
Imran R. Sheikh, S. Hinan Ahmed, Naoyo Mori, Anjan Gupta, Mark Mewissen, Suhail Allaqaband, Tanvir Bajwa. (2009) Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in Percutaneous Peripheral Intervention. JACC: Cardiovascular Interventions 2:9, 871-876
CrossRef261
Joanna J. Wykrzykowska, Patrick W. Serruys, Yoshinobu Onuma, Ton de Vries, Gerrit-Anne van Es, Pawel Buszman, Axel Linke, Thomas Ischinger, Volker Klauss, Roberto Corti, Franz Eberli, William Wijns, Marie-Claude Morice, Carlo di Mario, Robert Jan van Geuns, Peter Juni, Stephan Windecker. (2009) Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. JACC: Cardiovascular Interventions 2:9, 861-870
CrossRef262
Raffaele De Caterina. (2009) The current role of anticoagulants in cardiovascular medicine. Journal of Cardiovascular Medicine 10:8, 595-604
CrossRef263
Bernardo Cortese, Andrea Micheli, Andrea Picchi, Loria Bandinelli, Maria Gina Brizi, Silva Severi, Ugo Limbruno. (2009) Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Coronary Artery Disease 20:5, 348-353
CrossRef264
Paolo Gresele. (2009) Perioperative handling of antiplatelet therapy: watching the two sides of the coin. Internal and Emergency Medicine 4:4, 275-276
CrossRef265
Jan Steffel, Thomas F Lüscher. (2009) Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Journal of Cardiovascular Medicine 10:8, 616-623
CrossRef266
Michael Ray, Manjeet Juneja, Nicholas Bett, Darren Walters. (2009) A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 5:3, 330-335
CrossRef267
Gennaro Sardella, Massimo Mancone. (2009) Interventional cardiology: Effectiveness of stents in high-risk and 'real world' patients. Nature Reviews Cardiology 6:8, 502-503
CrossRef268
A. V. Finn, G. Nakazawa, F. Kolodgie, R. Virmani. (2009) Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?. European Heart Journal 30:15, 1828-1830
CrossRef269
Douglass A. Morrison. (2009) Primary percutaneous coronary intervention decision-making becomes more confusing: Where do glycoprotein 2b/3a inhibitors “fit” now?. Catheterization and Cardiovascular Interventions 74:2, 344-347
CrossRef270
IGOR MRDOVIC, LIDIJA SAVIC, JOVAN PERUNICIC, MILIKA ASANIN, RATKO LASICA, JELENA MARINKOVIC, ZORANA VASILJEVIC, MIODRAG OSTOJIC. (2009) Development and Validation of a Risk Scoring Model to Predict Net Adverse Cardiovascular Outcomes after Primary Percutaneous Coronary Intervention in Patients Pretreated with 600 mg Clopidogrel: Rationale and Design of the RISK-PCI Study. Journal of Interventional Cardiology 22:4, 320-328
CrossRef271
Chadwick D. Miller, Andra L. Blomkalns, Bernard J. Gersh, Charles V. Pollack, Gerard X. Brogan, Deborah B. Diercks, W. Frank Peacock, Gregg W. Stone, Judd E. Hollander, Steven V. Manoukian, James W. Hoekstra, . (2009) Safety and Efficacy of Bivalirudin in High-risk Patients Admitted Through the Emergency Department. Academic Emergency Medicine 16:8, 717-725
CrossRef272
R. B. Eslam, N. Reiter, A. Kaider, S. Eichinger, I. M. Lang, S. Panzer. (2009) Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. European Heart Journal 30:15, 1831-1836
CrossRef273
Dmitriy Kireyev, Edward C. Yun, Brian J. Page, William E. Boden. (2009) Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports 11:4, 267-275
CrossRef274
Joost DE Haeck, Niels JW Verouden, José PS Henriques, Karel T Koch. (2009) Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies. Future Cardiology 5:4, 385-402
CrossRef275
Liliana Grinfeld, Florencia Rolandi. (2009) Interventions for cardiovascular disease in women. Women's Health 5:4, 437-446
CrossRef276
Renato Valenti, Guido Parodi, Angela Migliorini. 2009. Platelet Glycoprotein IIb-IIIa Inhibitors. , 67-76.
CrossRef277
Somjot S. Brar, Gregg W. Stone. (2009) Advances in percutaneous coronary intervention. Current Cardiology Reports 11:4, 245-251
CrossRef278
Martin Moser, Christoph Bode. (2009) New antithrombotic agents in acute coronary syndromes. Current Opinion in Cardiology 24:4, 313-317
CrossRef279
Harvey D White. (2009) Strategies to minimize bleeding complications of percutaneous coronary intervention. Current Opinion in Cardiology 24:4, 273-278
CrossRef280
R. Mehran, S. J. Pocock, G. W. Stone, T. C. Clayton, G. D. Dangas, F. Feit, S. V. Manoukian, E. Nikolsky, A. J. Lansky, A. Kirtane, H. D. White, A. Colombo, J. H. Ware, J. W. Moses, E. M. Ohman. (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal 30:12, 1457-1466
CrossRef281
Simon R. Dixon, Cindy L. Grines, William W. O'Neill. (2009) The Year in Interventional Cardiology. Journal of the American College of Cardiology 53:22, 2080-2097
CrossRef282
F. Van de Werf. (2009) Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist--from evidence to recommendations and practice. European Heart Journal Supplements 11:Suppl C, C31-C37
CrossRef283
C. W. Hamm. (2009) Bleeding management and pharmacological strategy in primary percutaneous coronary intervention. European Heart Journal Supplements 11:Suppl C, C9-C12
CrossRef284
Marco Roffi, Franz R. Eberli. (2009) Diabetes and acute coronary syndromes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 305-316
CrossRef285
Brendan J. Doyle, Charanjit S. Rihal, Dennis A. Gastineau, David R. Holmes. (2009) Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 53:22, 2019-2027
CrossRef286
G. Guagliumi. (2009) Emerging data and decision for optimizing STEMI management: the European perspective. European Heart Journal Supplements 11:Suppl C, C19-C24
CrossRef287
Z. Astroulakis, J. M. Hill. (2009) Does 'SWITCHing' from heparin to bivalirudin monotherapy result in a bleeding benefit?. European Heart Journal Supplements 11:Suppl C, C13-C18
CrossRef288
R. Mehran, G. W. Stone. (2009) New paradigms of care for STEMI focusing on mortality and attributable death analysis: what do device and drug trials teach us?. European Heart Journal Supplements 11:Suppl C, C4-C8
CrossRef289
Lars S. Maier, Magnus Baumhäkel, Michael Böhm. (2009) Hotline sessions presented at the American College of Cardiology Congress 2009. Clinical Research in Cardiology 98:6, 345-352
CrossRef290
Stone, Gregg W., Lansky, Alexandra J., Pocock, Stuart J., Gersh, Bernard J., Dangas, George, Wong, S. Chiu, Witzenbichler, Bernhard, Guagliumi, Giulio, Peruga, Jan Z., Brodie, Bruce R., Dudek, Dariusz, Möckel, Martin, Ochala, Andrzej, Kellock, Alison, Parise, Helen, Mehran, Roxana, . (2009) Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal of Medicine 360:19, 1946-1959
Full Text291
Sorin J. Brener. (2009) The Benefits of Platelet Glycoprotein IIb/IIIa Receptor Inhibition During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 53:18, 1674-1676
CrossRef292
A. Siddique, M. Butt, E. Shantsila, G. Y. H. Lip. (2009) New antiplatelet drugs: beyond aspirin and clopidogrel. International Journal of Clinical Practice 63:5, 776-789
CrossRef293
H. Thiele. (2009) Optimales prähospitales Management des ST-Strecken-Hebungsinfarktes. Clinical Research in Cardiology Supplements 4:S2, 142-149
CrossRef294
CINDY L. GRINES. (2009) A New Era of Drug-Eluting Stents. Journal of Interventional Cardiology 22, S1-S2
CrossRef295
Douglass A. Morrison. (2009) Is the glass 97% full, or 3% empty? Reinfarction and stent thrombosis after STEMI. Catheterization and Cardiovascular Interventions 73:5, 635-636
CrossRef296
Alessandro Colombo, Piera Merlini. (2009) The ischaemia/bleeding balance in PCI. The Lancet 373:9667, 872-873
CrossRef297
Ganesan Karthikeyan, Shamir R Mehta, John W Eikelboom. (2009) Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Review of Cardiovascular Therapy 7:3, 241-249
CrossRef298
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef299
Gregg W Stone. (2009) Ischaemia versus bleeding: the art of clinical decision-making. The Lancet 373:9665, 695-696
CrossRef300
Mathew Williams. (2009) Highlights from the Twentieth Annual Transcatheter Cardiovascular Therapeutics Meeting. The Journal of Thoracic and Cardiovascular Surgery 137:2, 509-511
CrossRef301
GILLES LEMESLE, LAURENT BONELLO, AXEL DE LABRIOLLE, DANIEL H. STEINBERG, PROBAL ROY, TINA L. PINTO SLOTTOW, REBECCA TORGUSON, KIMBERLY KANESHIGE, ZHENYI XUE, WILLIAM O. SUDDATH, LOWELL F. SATLER, KENNETH M. KENT, JOSEPH LINDSAY, AUGUSTO D. PICHARD, RON WAKSMAN. (2009) Impact of Bivalirudin Use on Outcomes in Nonagenarians Undergoing Percutaneous Coronary Intervention. Journal of Interventional Cardiology 22:1, 61-67
CrossRef302
Harvey D White. (2009) HORIZONS trial: a step forward for primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:2, 125-129
CrossRef303
Robert W. Yeh, Suzanne J. Baron, Joanne L. Healy, Eugene Pomerantsev, Iris A. McNulty, Ignacio Cruz-Gonzalez, Ik-Kyung Jang. (2009) Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef304
José A. Barrabés, Juan Sanchís, Pedro L. Sánchez, Alfredo Bardají. (2009) Actualización en cardiopatía isquémica. Revista Española de Cardiología 62, 80-91
CrossRef305
Arnoud W.J. van ‘t Hof, Marco Valgimigli. (2009) Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI. Drugs 69:1, 85-100
CrossRef306
Owayed M. Al Shammeri, Richard Crowell, Keir Stewart, Stephen Fort. (2009) Failed pericardiocentesis for acute cardiac tamponade: Two cases associated with bivalirudin administration during PCI. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef307
Stefano Savonitto, Nuccia Morici, Alice Sacco, Silvio Klugmann. (2009) Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients. Future Cardiology 5:1, 27-41
CrossRef308
Arne Kristian Schwarz, Uwe Zeymer. (2009) Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction. Future Cardiology 5:1, 43-49
CrossRef309
D. Antoniucci. (2008) The balance between bleeding and ischaemic complications in percutnaeous coronary intervention practice. European Heart Journal Supplements 10:Suppl J, J21-J25
CrossRef310
Steen D. Kristensen, Helmut Baumgartner, Barbara Casadei, Helmut Drexler, Eric Eeckhout, Gerasimos Filippatos, Keith A.A. Fox, Joep Perk, Luc A. Pierard, Don Poldermans, Heribert Schunkert, Panos E. Vardas, Ernst E. van der Wall, Kim Fox, Jeroen J. Bax. (2008) Highlights of the 2008 Scientific Sessions of the European Society of Cardiology. Journal of the American College of Cardiology 52:24, 2032-2042
CrossRef311
Bruce R. Brodie, Thomas Stuckey, William Downey, Angela Humphrey, Marcy Nussbaum, Sherry Laurent, Barbara Bradshaw, Chris Metzger, James Hermiller, Fred Krainin, Stanley Juk, Barry Cheek, Peter Duffy, Charles A. Simonton, . (2008) Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheterization and Cardiovascular Interventions 72:7, 893-900
CrossRef312
Patrick Müller, Stephan Rosenkranz, Oliver Adam, Florian Custodis, Michael Böhm. (2008) Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008. Clinical Research in Cardiology 97:12, 851-864
CrossRef313
G. De Luca. (2008) Adjunctive antithrombotic therapy during primary percutaneous coronary intervention. European Heart Journal Supplements 10:Suppl J, J2-J14
CrossRef314
Neil Goyal, Jennifer Stant, Francesca Esposito, Gina Piri, Michael Collins, Osman Sayan, Gerald Neuberg, Leslie Miller, Jeffery W. Moses, Gregg W. Stone, James Giglio, LeRoy E. Rabbani. (2008) Updating the Chest Pain Algorithm. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 7:4, 211-222
CrossRef315
Umesh U Tamhane, Hitinder S Gurm. (2008) The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opinion on Drug Safety 7:6, 809-819
CrossRef316
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef317
M. L. Fokkema, P. J. Vlaar, T. Svilaas, M. Vogelzang, D. Amo, G. F.H. Diercks, A. J.H. Suurmeijer, F. Zijlstra. (2008) Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. European Heart Journal 30:8, 908-915
CrossRef318
R. Iijima, G. Ndrepepa, J. Mehilli, R. A. Byrne, S. Schulz, F.-J. Neumann, G. Richardt, P. B. Berger, A. Schomig, A. Kastrati. (2008) Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. European Heart Journal 30:3, 290-296
CrossRef319
Kastrati, Adnan, Neumann, Franz-Josef, Mehilli, Julinda, Byrne, Robert A., Iijima, Raisuke, Büttner, Heinz Joachim, Khattab, Ahmed A., Schulz, Stefanie, Blankenship, James C., Pache, Jürgen, Minners, Jan, Seyfarth, Melchior, Graf, Isolde, Skelding, Kimberly A., Dirschinger, Josef, Richardt, Gert, Berger, Peter B., Schömig, Albert, . (2008) Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. New England Journal of Medicine 359:7, 688-696
Full Text320
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef321
Arnoud WJ van't Hof, Jurriën ten Berg, Ton Heestermans, Thorsten Dill, Reinhard C Funck, Wouter van Werkum, Jan-Henk E Dambrink, Harry Suryapranata, Gert van Houwelingen, Jan Paul Ottervanger, Pieter Stella, Evangelos Giannitsis, Christian Hamm. (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. The Lancet 372:9638, 537-546
CrossRef322
Thomas Cuisset, Harald Mudra, Oliver Muller, Pierre Vogt, Anne Angelillo-Scherrer, Kurt Huber. (2008) Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions. EuroIntervention 4:2, 183-186
CrossRef323
Gilles Montalescot. (2008) Mechanical reperfusion: treat well, treat on time too. The Lancet 372:9638, 509-510
CrossRef324
Morrow, David A., . (2008) Antithrombotic Therapy to Support Primary PCI. New England Journal of Medicine 358:21, 2280-2282
Full Text325
Giuseppe De Luca, Paolo Marino. (2008) Antithrombotic Therapies in Primary Angioplasty. Drugs 68:16, 2325-2344
CrossRef
